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Abstract: 
 
Background:  Schizophrenia is a prevalent and costly condition in the United 
States.  Many studies have been conducted on the schizophrenia populations 
receiving government sponsored insurance, but less is known about the 16% of 
the population that receives commercial insurance.  A better understanding of the 
utilization and outcomes in this population is essential to ensure that outreach 
programs target the groups most in need, that these programs are aimed at the 
most important aspects of utilization, and that those factors are tied to meaningful 
clinical outcomes. 
Objectives:  The purpose of this research has been to better understand the 
patient characteristics, utilization patterns, and outcomes in patients with 
schizophrenia that participate in commercial insurance plans.  Three studies 
have been completed to address the following specific aims:  1)  To describe the 
schizophrenia population, 2)  To determine if the sociodemographic, clinical, and 
employment characteristics of these patients are associated with their utilization 
patterns, and 3)  To determine if adherence to therapy is associated with the rate 
of hospitalization for mental health conditions. 
Methods:  In order to accomplish these goals several studies have been 
completed utilizing claims data from calendar years 2000 and 2001.  The first is a 
retrospective cohort analysis identifying relationships between utilization of first 
and second generation antipsychotics, switching between therapies, and 
combination therapy and patient characteristics; the second study identifies the 
associations between patient characteristics and adherence; the final study 
  
utilizes a retrospective cohort design to determine the association between 
adherence and hospitalizations. 
Results:  Patient characteristics are a significant predictor of utilization, with 
individuals living in the North Central region and individuals with comorbid bipolar 
disorder significantly more likely to use second generation antipsychotics.  
Adherence was associated with comorbid diabetes and mental health disorders. 
Adherence as measured by an MPR greater than or equal to 80% was 
associated with a lower risk of hospitalization due to mental health conditions. 
Conclusion:  This series of studies has identified significant associations between 
comorbidities and increased likelihood to switch medications, utilize a second 
generation antipsychotic, or combine therapies.  Comorbidities also increase the 
likelihood that someone will not be adherent to their therapy.  Low adherence to 
therapy in turn increases the likelihood of hospitalization.
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CHAPTER 1 
 
 
ANALYSIS OF THE DEMOGRAPHIC, EMPLOYMENT, AND CLINICAL 
CHARACTERISTICS OF ANTIPSYCHOTIC UTILIZERS IN A COMMERCIALLY 
INSURED POPULATION 
 
Formatted for submission to the Journal of Managed Care Pharmacy 
(JMCP), not yet submitted. 
     
 
 2 
Abstract: 
Background 
Schizophrenia is a difficult and expensive condition to treat.  In the United States, 
many individuals with this condition are managed by federal health insurance 
programs, as a result most database studies examine schizophrenia treatment at 
the VA, or in Medicare and Medicaid populations.  The purpose of this analysis is 
to better understand treatment patterns in the commercial population, where 16% 
of the schizophrenia population is managed. 
Methods 
A retrospective cohort study was conducted utilizing data from the Thomson 
Marketscan database between January 1, 2000 and December 31, 2001.  
Individuals with schizophrenia were identified based on documentation of an 
ICD-9 (295.xx) code during year one.  Three logistic regression models were 
then used to determine if there was an association between first and second 
generation antipsychotic use, switching, and combination of therapies; and 
demographic, clinical, and employment characteristics of the population. 
Results 
Second generation antipsychotic use was associated with living in the North 
Central area of the United States (OR 1.3, 95% CI 1.053 - 1.603), comorbid 
bipolar disorder (OR 1.271, 95% CI 1.072 - 1.507), and switching (OR 1.937, 
95% CI 1.568 - 2.393).  Individuals who switched therapy were nearly twice as 
likely to have been taking a first generation antipsychotic before the switch (OR 
1.962, 95% CI 1.583 - 2.431)  Combination therapies were less likely in the North 
 3 
Central (0.727, 95% CI 0.554 - 0.955) and Southern (0.534, 95% CI 0.411 - 
0.694) regions as compared to the North East. 
Conclusion 
There were significant associations between certain demographic, clinical, and 
employment characteristics and the antipsychotic therapies received by 
individuals in the commercial population.
 4 
Background: 
Prevalence 
 
Mental health disorders are prevalent in the United States, and treating 
these conditions can be difficult and expensive.  A study conducted by Kessler et 
al, found that the lifetime prevalence of schizophrenia for adults in the United 
States is between 0.3% and 1.6%.1  A systematic review of the literature found 
that the period prevalence of schizophrenia is between 0.13% and 0.82%.2  An 
evaluation of a commercially insured population found that the prevalence of 
schizophrenia in that group is near the lower end of the range, at about 0.13%.3  
Despite being less prevalent in the commercial population, people in this group 
make up a significant portion (16%) of the schizophrenic population.3 
 
Treatment Decisions 
 
 Finding an appropriate treatment for schizophrenia is difficult.  It can take 
up to sixteen weeks to see the positive effects of treatment,4 and even with 
effective treatment the negative symptoms of schizophrenia (such as social and 
emotional withdrawal, poor rapport, and blunted affect) are still common.5  As a 
result, roughly 74% of patients are expected to discontinue treatment during the 
first 18 months.6  In addition to difficulty finding and adjusting to a treatment, the 
adverse events associated with both first and second generation antipsychotics 
are associated with lower adherence.7  In first generation antipsychotics, the 
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extrapyramidal side effects were closely associated with discontinuation, while 
metabolic effects lowered adherence in users of Second Generation 
Antipsychotics,6,8  A study by Staring, et al, found that high adherence was 
associated with decreased quality of life, as was low adherence due to the 
balance of symptoms and adverse events.9  It has become clear that adequate 
treatment with antipsychotics will lower the mortality rate in the schizophrenia 
population,10 but there are also associations between antipsychotics and 
increased cardiovascular mortality that have yet to be fully understood.11 
There are several studies that have tried to define the best strategy for 
selecting an initial antipsychotic.  The CATIE and CutLASS studies were 
prospective open label trials, but the treatments included for study, population 
characteristics, and study limitations have limited the acceptance of their findings 
by clinicians.12  Several studies have provided support for the use of First 
Generation Antipsychotics.  In a Medicare population, Second Generation 
Antipsychotic users were significantly more likely to be hospitalized as compared 
to non-users, while First Generation Antipsychotic users had roughly the same 
hospitalization rate as non-users.13  CATIE found that users of perphenazine 
saved roughly $300-600 over users of Second Generation Antipsychotics.14  
Amongst Second Generation Antipsychotics, a review of the literature found no 
clear benefit to any one choice.15  Despite the limited support in the literature, 
and no preference in treatment guidelines, there has been a major shift in use of 
antipsychotics from the first to second generation agents.16  Race, age, and 
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comorbidities were all factors closely associated with the decision to use a 
second generation antipsychotic in a Veteran population.16   
The population utilizing antipsychotics is not limited to individuals with 
schizophrenia.  In an analysis of a Veterans population, 60.2% of the population 
had no indication of a schizophrenia or bipolar diagnosis.17  The most common 
off label use in this population was Post Traumatic Stress Disorder (PTSD) 
(about 40% of the population had this diagnosis).  In a Medicaid population in 
Oregon, only 15% of patients receiving had a documented diagnosis of 
schizophrenia.18 
In addition to adverse events, comorbidities complicate the treatment of 
schizophrenia.  It has been found that despite physician knowledge of the 
problem, schizophrenic patients still do not receive appropriate treatments for 
their comorbid conditions.19  Patients with these conditions are often diagnosed 
with both mental health and general health issues, with one of the most common 
in schizophrenics being bipolar disorder.20  In schizophrenia, comorbid 
depression is closely linked to relapses,21 and anxiety is diagnosed in roughly 
60% of the population.22  The major general comorbidities driving treatment 
decisions are diabetes and cardiovascular disease.23, 24  Diabetes occurs in 
10.3% of schizophrenics, as compared to 5.6% of the general population.25  In 
the schizophrenic population, these increased risks are associated with greater 
risk of death from comorbidities,26 and a nursing home admission rate in 40-64 
year olds that is 3.9 times higher than the general population.27 
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Switching and Combinations 
 
 Switching between antipsychotics is a fairly common practice.  The CATIE 
trial found that in the best case scenario, 36% of patients taking olanzapine 
remained on treatment at 18 months.  Only 17% of quetiapine patients, 26% of 
risperidone patients, and 20% of ziprasidone patients remained on these second 
generation antipsychotics at 18 months.  Perphenazine represented first 
generation antipsychotics in this trial, and 25% of patients remained persistent at 
18 months.14  In almost all cases patients switched to a second generation 
antipsychotic, in only 1.2% of treatment episodes did an individual move from 
second generation to first generation.  An earlier study by Menzin, et al, found 
that 58% of first generation antipsychotic users switched to another antipsychotic 
(most often a second generation antipsychotic) while only 33% of second 
generation antipsychotic users switched to another antipsychotic (also most often 
a new second generation antipsychotic).28 
 The use of combination therapy is highly controversial.  The practice has 
been observed in between 5% and 18% of the population according to a review 
of the literature.4  There is scant evidence that polypharmacy results in better 
outcomes for individuals,4 although patients taking multiple medications do 
demonstrate poorer adherence.29  The most common combinations seen in 
database analyses involve two second generation antipsychotics, or a first and a 
second generation medication.30  The Joint Commission for Quality Improvement 
has laid out a set of narrow guidelines where combinations of two or more 
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antipsychotics might be reasonable, such as in patients utilizing Clozapine, 
multiple failed trials of monotherapy, or if discharged from a hospitalization with 
two or more medications.31 
 
Study Purpose and Justification 
 
 There have been many studies conducted to better understand the 
populations utilizing antipsychotics.  The vast majority of the literature identified 
above focuses on specific populations with a high incidence of schizophrenia, 
those individuals utilizing Medicaid and VA programs.  The commercial 
population likely differs significantly from the Medicaid and VA groups where 
patients are typically older, and (especially in the VA) more likely to be male.16, 28  
This population is also different from the CATIE population, in which 85% of the 
population was unemployed.6  A better understanding of how antipsychotic 
medications are utilized within commercial populations is critical.  Sixteen percent 
of schizophrenics receive services through private insurance.3 Programs 
designed to better manage these populations will utilize the improved information 
to better understand their participants.32, 33 
The goal of this analysis is to describe the primary medication taking 
characteristics of commercially insured patients utilizing antipsychotic 
medications; these characteristics are:  the use of first or second generation 
agents, switching treatments, and combination of treatments.  These 
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characteristics will be examined in relationship to the demographic, clinical, and 
employment characteristics of the patients.   
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Methods: 
Study Design: 
 
A retrospective cohort study was conducted utilizing the Thompson 
MarketScan database.  Those individuals utilizing antipsychotic medications, and 
diagnosed with schizophrenia were identified.  The primary treatment outcomes 
studied were choice of first or second generation antipsychotic, switching of 
treatments, and use of combination treatment.  Associations between these 
outcomes and the demographic, clinical, and employment characteristics of the 
populations were assessed. 
 
Data: 
 
Data for this analysis was made available through the Thomson Medstat 
dissertation support program.  This program provides access to de-identified data 
in the MarketScan database from years 2000 and 2001.  This database contains 
enrollment and demographics data, as well as medical and pharmacy claims for 
nearly 5.9 million individuals, including employees and their dependents working 
for large companies spread across the United States, and insured by roughly 100 
different payers. 
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Inclusion Criteria: 
 
Continuous enrollment is a key criterion for inclusion in this analysis.  
Although this requirement narrows the study population significantly, it is 
essential to ensure that key events such as prescription dispensings and 
encounters with medical professionals are recorded in the database, and 
available for the description of the population.  Individuals over 65 years of age 
during the study period were also excluded from the study population in order to 
avoid biases resulting from missing data associated with the coordination of 
benefits between Medicare and commercial insurers.  Individuals under the age 
of 18 were excluded in order to avoid similar benefit coordination issues in a 
pediatric environment.  Patients also had to have at least one diagnosis code 
indicating schizophrenia during the 2 year study period (Table I-1).  
 
Operational Definitions: 
 
Continuous enrollment was defined as having 366 days of continuous 
enrollment in 2000, and 365 days of continuous enrollment in 2001 with both 
medical and pharmacy coverage.  This data was abstracted from the enrollment 
data sets provided.   
Diagnoses for specific conditions were identified through the presence of 
one or more ICD-9 codes in the inpatient or outpatient records between January 
1, 2000 and December 31, 2001.  Anxiety, Bipolar Disorder, Depression, 
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Schizophrenia, Other Mental Health Disorders not included above, and Diabetes 
were all identified.  The specific list of ICD-9 codes used to identify these 
conditions is provided in table I-1.  This methodology is similar to that used in a 
variety of other studies,3, 34-36 and validated by Rawson, et al, in 1997.36    
A treatment episode with a given therapy was defined as receipt of at least 
2 dispensings on different days within the study period.  Individuals with no 
treatment episodes were excluded from the bivariate and multivariate analyses.  
Therapies were defined as a “new treatment” if there was no record of that 
treatment being received during the six months preceding the first fills. The 
“therapeutic period” for a treatment was defined as the time from the first fill, to 
the date of the last fill plus the last days supply.  “Combination Therapy” was 
defined as two treatments overlapping by a minimum of 90 consecutive days.  A 
“switch” in therapy is defined as a change from one treatment to another where 
there is no more than a 90 day gap in therapy, and no more than 90 days of 
overlap in therapy.  A “gap” in treatment is defined as a period of 90 days or 
more following the end of a therapeutic period.  Studies have typically used 
periods of 30 to 90 days to define gaps in therapy.34, 35, 37  This study utilized the 
90 day period to match the longest days supply routinely received by patients. 
Demographic variables were examined for missing or obviously erroneous 
data through examination of distributions and outliers.  An individual’s age was 
defined as the difference between their birth year, and the year 2000.  There 
were no instances in the data where an individual had more than 1 gender on 
record.  Descriptions of employment type (primary vs. secondary policy holder, 
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full time vs. part time, and hourly vs. salaried) and geographic variables were 
defined for each individual as the value that turned up most often for that 
individual (if more than one value was available). 
 
Bivariate Statistical Analysis: 
 
Bivariate analyses were conducted in order to determine the associations 
between the three outcomes (antipsychotic generation choice, switching, and 
combination use) and the demographic, clinical, and employment variables.  The 
students t-test was utilized for age, the only normally distributed continuous 
variable.  Chi-square analysis was conducted for the binomial and categorical 
variables. 
 
Multivariate Statistical Analysis: 
 
Because of the potential for strong relationships between many of the 
explanatory variables explored in the bivariate statistical analysis, logistic 
regression was also used in each of the populations to examine the following: 
1. Factors associated with the decision to use a second generation 
antipsychotic or a first generation antipsychotic 
2. Factors associated with switching 
3. Factors associated with combination use 
 
The dependent variables tested were:  type of antipsychotic, switch, and 
combination.  The independent variables included in each model were:  age, 
gender, region, rural / urban, full time employment, employee or dependent, 
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industry, and comorbidies (schizophrenia, bipolar disorder, depression, anxiety, 
other mental health, and diabetes).  Variables were included in the model if they 
were found to be associated with the outcome variable in bivariate testing (p < 
0.2).  The exceptions are age and gender, which were included regardless due to 
their importance in understanding the make-up of the population.  Interaction 
terms including the various combinations of age group, gender, and 
comorbidities were also included if they were associated with the dependent 
variable as measured by the chi-square test with a significant p-value (<0.2).  
Chi-square analysis was also used to assess several potential associations 
amongst independent variables to determine if they were independent.  If the 
variables were not independent (chi-square value was less than 0.05), the less 
important variable was dropped from consideration for the model.  Stepwise 
backwards elimination was used to optimize the model, using the -2 log likelihood 
to test the significance of changes.  Multicollinearity was assessed based on the 
variation inflation factor (VIF), and eignevalues.  These were calculated utilizing a 
separate model with the proc reg function in SAS with the VIF, TOL, and collin 
options.  Hosmer-Lemeshow was used to assess goodness of fit.  
. 
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Results: 
Study Population 
 
A diagnosis for schizophrenia was recorded for 2,156 individuals (0.15% 
of the eligible population) between 2000 and 2001; table I-2 describes their 
demographic characteristics.  Of the 2,156, a total of 1,517 (70.4%) received at 
least 2 dispensings for the same antipsychotic.  Figure I-1 describes the 
population waterfall.  A majority of this population was female (N=1,244 [57.7%]).  
The biggest group of schizophrenic patients lived in the south (43.7%), with 
27.1% in North Central, 24.7% in the North East, and the remaining 4.4% in the 
West.  19.3% of the population lived in a rural setting.  This reflects the general 
distribution of the population in the database.  Of the population eligible for 
inclusion in this study, 0.15% had one or more documented ICD-9 codes 
indicating schizophrenia. 
A majority of this population (56.3%) were active full time employees.  
Manufacturing was the most common known industry, with 32.0% (N=690) of 
individuals employed.  Approximately half of the individuals in this population 
were spouses or dependents (1098 [50.9%]).  There were more hourly workers 
than salary workers in this population (N=593 and 470 respectively).  Details 
regarding employment in this population are in table I-2. 
Comorbid conditions are described in table I-2.  Bipolar disorder was 
identified in 29% (N=637) of this population, depression was documented in 489 
(22.7%) individuals, and anxiety was documented in 245 (11.4%).  Other mental 
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health disorders not listed above were identified in claims for 1,181 (54.8%) 
people.  Diabetes was documented in 355 (16.5%) of individuals identified in this 
group. 
There were 3,239 individual treatment episodes for antipsychotics in the 
schizophrenic population (table I-3), which averages to 1.5 per patient or 2.1 for 
each patient that used at least 2 fills of an antipsychotic.  Second generation 
antipsychotics were utilized by 56.2% (N=1212) of the population, and first 
generation antipsychotics are used by 27.4% (N=591) of the schizophrenic 
population identified.  Records indicating 2 or more dispensings of an 
antipsychotic are absent in 29.6% (N=639) of the population with documentation 
of schizophrenia, indicating that they are either untreated during this study 
period, or are receiving treatment through a source that is not recorded in the 
claims.  The most commonly received antipsychotics were olanzapine and 
risperidone (received by 27.1% and 25.2% of the population respectively), table 
I-3 describes the rate of use for the remaining treatments. 
Switching between one or more antipsychotics occurred prior to 21.7% 
(N=702) of the treatment episodes (in 13.6% of the population), while 
combination therapy was observed in 421 (13.0%) treatment episodes (in 12.9% 
of the population).  The most common switches were between second generation 
antipsychotics.  Table I-4 demonstrates the switches identified in the 
antipsychotic users.  The majority of combinations were with first and second 
generation antipsychotics (N=262), with combinations of two second generation 
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antipsychotics also common (N=136).  Table I-5 demonstrates the combinations 
utilized by this population. 
 
Bivariate Analysis  
 
 First generation antipsychotic users were on average 3.1 years older than 
those using second generation antipsychotics in this population (table I-6), and 
3.6% more individuals in the North East received a first generation antipsychotic 
than individuals living elsewhere; 9.2% more individual patients diagnosed with 
comorbid bipolar disorder received a second generation antipsychotic than those 
who were not diagnosed.  After switching medications, the frequency of second 
generation antipsychotic use was 14.5% higher than if they were treatment naïve 
or starting on a therapy after a long gap. 
 Patients switching medications were on average, younger than those who 
did not switch, although there was no difference in age for those using 
combination treatments.  Table I-7 describes associations with switching and 
combination use in this population.  Patients with bipolar disorder in addition to 
schizophrenia were more likely to switch medications (p<0.0001).  Those with 
anxiety were more likely to switch (p<0.001), but less likely to use combinations 
(p= 0.004).  Type of employment was not associated with the rate of switching. 
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Multivariate Analysis: 
 
 In this population antipsychotic type was modeled against age, gender, 
region, comorbid diagnoses (bipolar disorder, depression, anxiety, and diabetes), 
switching, combination use, and employment variables for the full model.  Salary, 
full time employment, combinations, and anxiety and depression diagnoses did 
not contribute significantly to the model (see table I-8).  The final model had a 
reasonable goodness-of-fit with c=0.839, and the Hosmer-Lemeshow p-value of 
0.353.  The model indicated that as compared with residents of the North East 
region, individuals in the North Central region were more likely to receive a 
second generation antipsychotic (OR 1.3, 95% CI 1.053 – 1.603).  In this 
population, individuals with a comorbid diagnosis of bipolar disorder were 27.1% 
(OR 1.271, 95% CI 1.072% – 1.507%), and individuals with other mental health 
conditions were 48.9% (OR 1.489, 95% CI 1.266 - 1.750) more likely to receive a 
second generation antipsychotic as compared with patients without the condition.  
Individuals who had switched from another medication were nearly twice as likely 
as those who had not switched to receive a second generation antipsychotic (OR 
1.937, 95% CI 1.568 – 2.393).  Age, gender, and comorbid diabetes were not 
significant (table I-9). 
 Switching therapy was modeled against age, gender, region, diagnoses, 
use of a second generation antipsychotic, combination use, and responsibility for 
insurance coverage.  Responsibility for coverage was removed in the final model 
due to lack of significance (table I-8).  This had a reasonable goodness-of-fit with 
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c=0.848, and the Hosmer-Lemeshow p-value of 0.275.  Prior to switching, 
individuals were nearly twice as likely to have received first generation 
antipsychotics, as compared to a second generation antipsychotic (OR1.929, 
95% CI 1.561 – 2.384) (table I-10).  Individuals with comorbid bipolar disorder 
were 39% (OR 1.393 95% CI 1.163 – 1.668) more likely than those without a 
bipolar diagnosis to switch antipsychotics. 
 Use of combinations of treatments in the schizophrenia population was 
modeled against age, gender, rural location, region, diagnoses, use of a second 
generation antipsychotic, switching, and employment variables.  Rural location, 
use of a second generation antipsychotic, and diagnoses besides anxiety were 
removed from the model because they did not make a significant contribution to 
the model (table I-8).  The model had a good fit with c=0.895, and the Hosmer-
Lemeshow p-value = 0.926.  Individuals in the North East were more likely to 
receive medications in combination as compared with patients in the North 
Central and South regions (table I-11).  Full time workers (OR 0.653, 95% CI 
0.523 - 0.989), and those listed as primary on their insurance coverage (OR 
0.785, 95% CI 0.623 - 0.815) were less likely than others to have combination 
therapies. 
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Discussion: 
 
The results of this study draw some significant distinctions between the 
commercially insured and government insured populations receiving 
antipsychotic therapy for schizophrenia.  Understanding these differences will 
improve the ability of the commercial managed care organizations to direct 
resources and focus on ensuring appropriate care for those individuals most 
likely to be switching or combining therapy, and help to ensure that those 
prescribing decisions are appropriate.  The ability to do this could lead to 
improved quality of care and lower overall costs for both the payors and patients. 
 
Utilization of First vs. Second Generation Antipsychotics 
 
Age was a significant predictor of medication choice, with older individuals 
more likely to receive first generation antipsychotics than younger patients.  One 
other study was identified that has used claims data to identify factors associated 
with utilization of antipsychotics.  The association between older age and lower 
frequency of second generation antipsychotic use was similar to that identified in 
a Texas Veteran’s population by Yang, et al.16  In agreement with our findings 
Yang et al reported that patients having a documented diagnosis of bipolar 
disorder or other mental health disorders had an increased likelihood of receiving 
a second generation antipsychotic. However, the Yang et al study did not assess 
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the influence of a diagnosis of diabetes, region, or switching between 
medications.   
The differences identified in prescribing by region between the North East and 
North Central areas of the country are supported by a variety of literature 
describing differences in medical costs and quality throughout the United States.  
Some of the most described examples of this are the regional differences in cost 
and quality in Medicare.  Zhang et al found that in the South East there are 
significantly higher rates (up to 44%) of potentially inappropriate prescribing to 
the elderly, compared to New England where the highest rates observed were 
below 21%.38 
 
Switching Rates 
 
Individuals can switch between antipsychotics for a variety of reasons, 
including adverse events, lack of effectiveness, or concerns about cost.  
Although patients are commonly more adherent to treatment after a switch, there 
are potential adverse events associated with switching, especially if patients do 
not titrate propperly.39  The results of this study are useful in establishing a 
baseline switch rate for individuals in a commercial population. 
The likelihood of having switched therapies was twice as high among those 
individuals currently using second generation antipsychotics, and roughly 40% 
higher in those with bipolar disorder or depression.  Age and gender were not 
significant influences on medication switching.  Although having a comorbid 
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diagnosis of diabetes was associated with increased use of first generation 
antipsychotics, those with diabetes were also 34.5% more likely to switch 
medications.  The increased rate of switching makes sense in those individuals 
with a more complex clinical situation due to the increased likelihood of adverse 
events and poorer adherence leading to inadequate outcomes,28 and these 
trends are also supported by literature evaluating a Medicaid population.28, 39  The 
rate of switching from first generation antipsychotics to second generation 
antipsychotics was also similar to that seen in the CATIE trial, which found that 
18% of patients switched medications during an 18 month time period.14 
 
Use of combination therapy 
 
The frequency of combinations between first generation antipsychotics and 
second generation antipsychotics, as well as multiple second generation 
antipsychotics seen in our population was similar to that seen in the literature.30  
The overall combination rate of 12.9% was in the range identified in a review by 
Stahl, et al, which was 5-18% of all users of these medications within outpatient 
populations.4  Combination therapy was significantly less common in individuals 
working full time, or currently responsible for providing insurance coverage.  
These factors are likely to be closely associated with disease severity, although 
given the short time period studied, it cannot be determined whether they simply 
are better responders to monotherapy, or if this group has a less severe 
underlying condition overall.  Generally, the existing literature does not support 
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the utilization of polypharmacy, due to a lack of improved outcomes, increased 
adverse events, and higher costs,4 although there are narrow circumstances in 
which combining multiple medications may be necessary and acceptable, such 
as after failure to respond in 3 or more trials of monotherapy, individuals using 
Clozapine, and those released from inpatient treatment with combination 
therapy.31 
Combination therapy was also less common in individuals living in the North 
Central and Southern regions as compared to the North East.  Further study is 
needed to understand why these regional differences exist, and no other studies 
conducted in the United States have been identified that address this 
discrepancy in therapy across regions.  A Danish study identified regional 
differences in the understanding of clinical guidelines as one possible reason for 
differences in polypharmacy.40 
 
Limitations 
 
Although the goal of this analysis was to ensure generalizability to the 
commercially insured US population, the requirement of 2 years continuous data 
may have limited the inclusion of some of the more severe patients that were not 
enrolled for the entire study period. However, the proportion of schizophrenic 
individuals excluded from the study population due to our continuous enrollment 
requirement was smaller than the proportion of the overall population.  Because 
the time available in the data set is relatively short, it was not possible to reliably 
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establish a temporal sequence, limiting the ability to understand the relationships 
between the observed factors and medication choice, switching, or combination 
use.  The age of the data also limits generalizability due to the addition of new 
treatments and guidelines that may have subsequently changed practice over 
time. 
This study is reliant on claims data submitted by physicians and pharmacies 
for the purposes of billing, therefore there are some limitations seen across 
retrospective database analyses.  Pharmacy data indicating a medication is 
dispensed do not ensure that the medications are actually consumed, 
additionally individuals paying cash or receiving samples of their medication from 
their physician will not have records.  Finally, diagnosis coding can be inaccurate, 
with some individuals with documentation of schizophrenia not having the 
condition, as well as the reverse, individuals diagnosed that do not have full 
documentation. 
Smoking and obesity are confounders in the schizophrenia population that 
could not be addressed.  Because of the metabolic side effects of second 
generation antipsychotics, obesity may have been an unobserved factor 
influencing an increased use of first generation antipsychotics.  Smoking has 
been associated with lower adherence to medications,41 but it is not clear 
whether it would impact combination therapy, switching, or the choice between 
first and second generation antipsychotics. 
 
Conclusions 
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This analysis demonstrates the significant differences between a 
commercially insured schizophrenia population and the more commonly 
evaluated populations in federally insured programs.  Comorbidities with diabetes 
and bipolar disorder were key drivers of increased therapy switches, while age 
and gender played a smaller role than that observed in other populations.  
Additional study is necessary to determine if these factors also impact an 
individual’s ability to adhere to therapy. 
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Figures: 
 
Figure I-1:  Inclusion / Exclusion Criteria Flowchart 
 
 
 
 
MarketScan Population: 
5,829,954 
Exclude: Less than 24 months  
continuous enrollment: 
3,887,128 (66.7%) 
Exclude: Less than 18 years of age: 
505,864 (8.7%) 
Exclude: Over 65 years of age: 
8,613 (0.1%) 
 
Population Meeting Demographic Criteria: 
N = 1,428,349 (24.5% of total population) 
Individuals with >=1 ICD code for Schizophrenia (study sample): 
N = 2,156 (0.2%) 
Rx Treated Schizophrenic Population 
1,517 (0.1%) 
 27 
Tables: 
 
Table I-1:  ICD-9 Codes used for identifying diagnoses with 
primary conditions and comorbidities 
Condition ICD-9 Codes Included 
Schizophrenia 295 - 295.95 
Bipolar Disorder 296 - 296.99 
Anxiety 300 - 300.09 
Depression 311, 300.4 
Other Mental Health 290 - 319, except for those listed above 
Diabetes 250.00 – 250.99 
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Table I-2:  Demographics of patients with a diagnosis for schizophrenia 
      
N / Mean % / SD 
Total Population N 2,156 100.0% 
Demographic Age Mean (SD) 45.5 11.9 
Region Northeast 533 24.7% 
North Central 584 27.1% 
South 942 43.7% 
West 95 4.4% 
Unknown 2 0.1% 
Comorbidities Mental Health 
Conditions 
Bipolar 637 29.5% 
Depression 489 22.7% 
Anxiety 245 11.4% 
Other Mental Health 1,181 54.8% 
Others Diabetes 355 16.5% 
Employment Employment 
Status 
Active Full Time 1,213 56.3% 
Active Part Time or Seasonal 25 1.2% 
Early Retiree 800 37.1% 
Medicare Eligible Retiree 13 0.6% 
Retiree (status unknown) 34 1.6% 
COBRA Continuee 19 0.9% 
Long Term Disability 18 0.8% 
Surviving Spouse/Depend. 12 0.6% 
Other/Unknown 22 1.0% 
Industry Oil & Gas Extraction, Mining 0 0.0% 
Manufacturing, Durable Goods 514 23.8% 
Manufacturing, Nondurable 
Goods 176 8.2% 
Transportation, 
Communications, Utilities 392 18.2% 
Finance, Insurance, Real 
Estate 43 2.0% 
Services 273 12.7% 
Unknown / Missing 758 35.2% 
Relationship to 
Employee 
Employee 1,058 49.1% 
Spouse 708 32.8% 
Child/Other 390 18.1% 
Employment 
Class 
Salary Non-union 146 6.8% 
Salary Union 166 7.7% 
Salary Other 158 7.3% 
Hourly Non-union 47 2.2% 
Hourly Union 171 7.9% 
Hourly Other 375 17.4% 
Non-union 175 8.1% 
Union 51 2.4% 
Unknown 857 39.7% 
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Table I-3:  Frequency and percentage of the use of antipsychotic 
medication types within the study population  
  
N* % 
Total Population 2156 100.0% 
No Treatment 639 29.6% 
Second 
Generation 
Any Second Generation 1212 56.2% 
Clozapine (Clozaril) 112 5.2% 
Ziprasidone (Geodon) 207 9.6% 
Risperidone (Risperdal) 544 25.2% 
Quetiapine (Seroquel) 294 13.6% 
Olanzapine (Zyprexa) 584 27.1% 
First 
Generation 
Any First Generation 591 27.4% 
Haloperidol (Haldol) 163 7.6% 
Loxapine (Loxitane) 35 1.6% 
Thioridazine (Mellaril) 61 2.8% 
Molindone (Mobane) 12 0.6% 
Thiothixene (Navane) 75 3.5% 
Pimozide (Orap) 3 0.1% 
Fluphenazine (Prolixin) 80 3.7% 
Mesoridazine (Serentil) 7 0.3% 
Trifluoperazine (Stelazine) 93 4.3% 
Chlorpromazine (Thorazine) 59 2.7% 
Perphenazine (Trilafon) 65 3.0% 
*Total N does not sum due to use of combination 
therapies  
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Clozapine 
(Clozaril)
Olanzapine 
(Zyprexa)
Quetiapine 
(Seroquel)
Risperidone 
(Risperdal)
Ziprasidone 
(Geodon)
Second 
Generation 
Antipsychotics
Chlorpromazine 
(Thorazine)
Droperidol 
(Inapsine)
Fluphenazine 
(Prolixin)
Perphenazine 
(Trilafon)
Pimozide (Orap)
Thioridazine 
(Mellaril)
Thiothixene 
(Navane)
Haloperidol 
(Haldol)
Loxipine 
(Loxitane)
Mesoridazine 
(Serentil)
Molindone 
(Mobane)
Trifluoperazine 
(Stelazine)
First Generation 
Antipsychotics
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Clozapine 
(Clozaril)
Olanzapine 
(Zyprexa)
Quetiapine 
(Seroquel)
Risperidone 
(Risperdal)
Ziprasidone 
(Geodon)
Second 
Generation 
Antipsychotics
Chlorpromazine 
(Thorazine)
Trifluoperazine 
(Stelazine)
First Generation 
Antipsychotics
Mesoridazine 
(Serentil)
Molindone 
(Mobane)
Perphenazine 
(Trilafon)
Pimozide (Orap)
Thioridazine 
(Mellaril)
Thiothixene 
(Navane)
Droperidol 
(Inapsine)
Fluphenazine 
(Prolixin)
Haloperidol 
(Haldol)
Loxipine 
(Loxitane)
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Table I-6:  Bivariate analysis of demographic, clinical, and employment factors 
associated with use of a first or second generation antipsychotic in the population 
diagnosed with schizophrenia 
  
  
  
  
First 
Generation 
Antipsychotic 
Second 
Generation 
Antipsychotic p-value 
N % N % 
Age mean (SD) 47.1 10.8 44 12.4 <0.0001 
Gender Male 404 30.2 932 69.8 0.836 
Female 569 29.9 1,334 70.1 
Location Rural 186 30.7 419 69.3 0.676 
Non-Rural 787 29.9 1,847 70.1 
North East 275 32.7 565 67.3 0.048 
Not North East 698 29.1 1,701 70.9 
North Central 248 27.0 669 73.0 0.019 
Not North Central 725 31.2 1,597 68.8 
South 401 30.4 920 69.6 0.745 
Not South 572 29.8 1,346 70.2 
West 46 30.3 106 69.7 0.951 
Not West 927 30.0 2,160 70.0 
Diagnoses Bipolar Disorder 295 24.3 917 75.7 
<0.0001 
No Bipolar Disorder 678 33.5 1,349 66.5 
Anxiety 103 25.8 297 74.2 0.046 
No Anxiety 870 30.6 1,969 69.4 
Depression 211 24.2 622 75.8 
<0.0001 
No Depression 762 32.2 1,604 67.8 
Other Mental Health 495 25.2 1,468 74.8 
<0.0001 
No Other Mental Health 478 37.5 798 62.5 
Diabetes 203 34.9 379 65.1 0.005 
No Diabetes 770 29.0 1,887 71.0 
Switching Switched To 131 18.7 571 81.3 
<0.0001 
Not post switch 842 33.2 1,695 66.8 
Combinations Combined 143 34.0 278 66.0 0.060 
Not Combined 830 29.5 1,988 70.5 
Employment Full Time 1,013 44.7 1,253 55.3 
0.146 Part Time / Retired / 
Unemployed 462 47.5 511 52.5 
Responsible for 
Coverage 1,200 53.0 1,066 47.0 0.696 
Dependent 508 52.2 465 47.8 
Salary 1,754 77.4 512 22.6 0.038 
Non-Salary / Unknown 785 80.7 188 19.3 
Hourly 1,643 72.5 623 27.5 0.090 
Non-Hourly / Unknown 677 69.6 296 30.4 
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N % N % N % N %
Age mean (SD) 43.3 12.3 45.2 12.0 0.000 44.9 11.6 44.8 12.1 0.857
Male 272 20.4 1,064 79.6 172 12.9 1,164 87.1
Female 430 22.6 1,473 77.4 249 13.1 1,654 86.9
Rural 128 21.2 477 78.8 69 11.4 536 88.6
Non-Rural 574 21.8 2,060 78.2 352 13.4 2,282 86.6
North East 172 20.5 668 79.5 140 16.7 700 83.3
Not North East 530 22.1 1,869 77.9 281 11.7 2,118 88.3
North Central 197 21.5 720 78.5 124 13.5 793 86.5
Not North Central 505 21.7 1,817 78.3 297 12.8 2,025 87.2
South 285 21.6 1,036 78.4 132 10.0 1,189 90.0
Not South 417 21.7 1,501 78.3 289 15.1 1,629 84.9
West 43 28.3 109 71.7 23 15.1 129 84.9
Not West 659 21.3 2,428 78.7 398 12.9 2,689 87.1
Bipolar Disorder 337 27.8 875 72.2 145 12.0 1,067 88.0
No Bipolar Disorder 365 18.0 1,662 82.0 276 13.6 1,751 86.4
Anxiety 115 28.8 285 71.3 34 8.5 366 91.5
No Anxiety 587 20.7 2,252 79.3 387 13.6 2,452 86.4
Depression 263 30.1 610 69.9 96 11.0 777 89.0
No Depression 439 18.6 1,927 81.4 325 13.7 2,041 86.3
Other Mental Health 517 26.3 1,446 73.7 248 12.6 1,715 87.4
No Other Mental Health 185 14.5 1,091 85.5 173 13.6 1,103 86.4
Diabetes 139 23.9 443 76.1 80 13.7 502 86.3
No Diabetes 563 21.2 2,094 78.8 341 12.8 2,316 87.2
Switched To N/A N/A N/A N/A 3 0.4 699 99.6
Not post switch N/A N/A N/A N/A 418 16.5 2,119 83.5
Combined 3 0.7 418 99.3 N/A N/A N/A N/A
Not Combined 699 24.8 2,119 75.2 N/A N/A N/A N/A
Full Time 394 22.3 1,370 77.7 198 11.2 1,566 88.8
Part Time / Retired / 
Unemployed 308 20.9 1,167 79.1 223 15.1 1,252 84.9
Primary Policy Holder 316 20.6 1,215 79.4 181 11.8 1,350 88.2
Dependent 386 22.6 1,322 77.4 240 14.1 1,468 85.9
Salary 152 21.7 548 78.3 100 14.3 600 85.7
Hourly / Unknown 550 21.7 1,989 78.3 321 12.6 2,218 87.4
Hourly 189 20.6 730 79.4 114 12.4 805 87.6
Salary / Unknown 513 22.1 1,807 77.9 307 13.2 2,013 86.8
Switching
Combinations
Diagnoses
0.528
0.252
0.001
0.060
0.336
Table I-7:  Bivariate analysis of demographic, clinical, and employment factors associated with switching between and 
combinations of antipsychotics in the population diagnosed with schizophrenia
Employment
Gender
N/A
0.004
0.554
<0.0001
0.861
0.196
0.000
0.577
0.040
0.445
<0.0001
0.423
Combination
Combination Non-Combination p-value
0.176
0.317
0.177
0.976
0.153
N/A
0.000
<0.0001
<0.0001
<0.0001
Switching
Switch Non-Switch
p-value
0.128
0.733
0.328
0.869
0.043
<0.0001
Location
0.910
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Dependent 
Variable Iteration Description
Log 
Likelihood
-2 Log 
Likelihood Model DF
DF from 
previous model
chi-square 
critical value P-value
1 Full Model* 3800.453 14
2 Full Model - Salary 3800.474 0.042 13 1 3.84 >0.05
3 Full Model - Salary, Full 3801.677 2.406 12 1 3.84 >0.05
4
Full Model - Salary, Full 
Time, Comb 3801.83 0.306 11 1 3.84 >0.05
5 Full Model - Salary, Full Time, Comb, Anxiety 3801.83 0 10 1 3.84 >0.05
6 Full Model - Salary, Full Time, Comb, Anxiety, 3803.586 3.512 9 1 3.84 >0.05
7
Full Model - Salary, Full 
Time, Comb, Anxiety, 
Depression, Region
3811.36 15.548 6 3 7.81 <0.05
Dependent 
Variable Iteration Description
Log 
Likelihood
-2 Log 
Likelihood Model DF
DF from 
previous model
chi-square 
critical value P-value
1 Full Model* 3224.655 14
2 Full Model - Covered** 3225.013 0.716 13 1 3.84 >0.05
3
Full Model - Covered, 
Region 3229.903 9.78 10 3 7.81 <0.05
Dependent 
Variable Iteration Description
Log 
Likelihood
Difference in 
-2 Log 
Likelihood Model DF
Difference in 
DF from 
previous model
chi-square 
critical value P-value
1 Full Model* 2259.84 17
2 Full Model - Rural 2259.84 0 16 1 3.84 >0.05
3 Full Model - Rural, SGA 2260.001 0.322 15 1 3.84 >0.05
4
Full Model - Rural, SGA, 
Depression 2260.152 0.302 14 1 3.84 >0.05
5
Full Model - Rural, SGA, 
Depression, Other Mental 
Health
2261.22 2.136 13 1 3.84 >0.05
6
Full Model - Rural, SGA, 
Depression, Other Mental 
Health, Bipolar Disorder
2261.257 0.074 12 1 3.84 >0.05
7
Full Model - Rural, SGA, 
Depression, Other Mental 
Health, Bipolar Disorder, 
Diabetes**
2262.092 1.67 11 1 3.84 >0.05
8
Full Model - Rural, SGA, 
Depression, Other Mental 
Health, Bipolar Disorder, 
Diabetes, Region
2285.674 47.164 8 3 7.81 <0.05
Table I-8:  Model fitting diagnostics for variables associated with the use of first or second generation antipsychotics, adherence, 
persistence, switching, and combination in the schizophrenia population
Second 
Generation 
Antipsychotic 
Use
*Full model includes:  Age, gender, region, diagnoses, switching, combination, and employment variables
**Final model includes:  Age, gender, region, diagnosis, and combination
Switching
*Full model includes:  Age, gender, region, diagnoses, use of second generation antipsychotic, combination, and responsibility for coverage
**Final model includes: Age, gender, region, diagnoses, use of second generation antipsychotic, and combination
*Full model includes:  Age, gender, rural / non-rural, region, diagnoses, use of second generation antipsychotic, switching, and employment variables
**Final model includes:  Age, gender, region, diagnosis of anxiety, switching, and employment variables
Combination
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Table I-9:  Odds Ratios for the likelihood that a patient would receive a 
second generation antipsychotic as compared with a first generation 
antispychotic  
  
  Point 
Estimate 
95%Confidence Limits 
Demographic Male 0.919 0.783 1.08 
Age 0.981 0.974 0.988 
Region North East Reference     
North Central 1.3 1.053 1.603 
South 1.188 0.982 1.439 
West 0.919 0.624 1.354 
Clinical Bipolar 1.271 1.072 1.507 
Other Mental 
Health 
1.489 1.266 1.75 
Diabetes 0.852 0.698 1.039 
Switch 1.937 1.568 2.393 
 
 36 
 
Table I-10:  Odds Ratios for the likelihood that a patient would switch 
treatments, according to selected demographic and clinical characteristics.  
  
  Point Estimate 95%Confidence 
Limits 
Demographic Male 0.93 0.774 1.116 
Age 0.993 0.986 1.001 
Region North East Reference     
North Central 1.053 0.832 1.333 
South 1.145 0.92 1.425 
West 1.539 1.027 2.306 
Clinical Second Generation 
Antipsychotic 1.929 1.561 2.384 
Anxiety 1.17 0.912 1.501 
Bipolar 1.393 1.163 1.668 
Depression 1.435 1.181 1.744 
Other Mental Health 1.592 1.301 1.949 
Diabetes 1.345 1.081 1.695 
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Table I-11:  Odds Ratios for the likelihood of combination antipsychotic 
medication treatment, according to selected demographic and clinical 
characteristics.   
  
  Point Estimate 95%Confidence 
Limits 
Demographic Male 0.94 0.748 1.182 
Age 0.995 0.985 1.005 
Region North East Reference     
North Central 0.727 0.554 0.955 
South 0.534 0.411 0.694 
West 0.958 0.58 1.582 
Clinical Anxiety 0.643 0.44 0.94 
Switch 0.021 0.007 0.067 
Employment 
Full Time 0.653 0.523 0.989 
Responsible for 
Coverage 0.785 0.623 0.815 
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ADHERENCE TO ANTIPSYCHOTIC TREATMENTS IN A COMMERCIALLY 
INSURED POPULATION DIAGNOSED WITH SCHIZOPHRENIA 
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Abstract: 
Background 
Adherence and persistence to medications for schizophrenia is typically less than 
that seen in other classes of medication.  Additionally, studies of adherence to 
antipsychotics are often completed in populations with a high prevalence of 
schizophrenia, which may not be generalizable to the commercially insured 
population.  The purpose of this analysis was to determine the factors associated 
with adherence to therapy in a commercially insured population. 
Methods 
A retrospective cohort study was completed in order to determine if demographic, 
clinical, or employment characteristics described in administrative claims data 
are associated with adherence and persistence in this population.  Adherence 
was calculated based on a medication possession ratio of greater than 80%, and 
persistence was based on a gap of 90 days or more in therapy. 
Results 
There were 1,086 individuals identified with an ICD-9 code indicating 
schizophrenia and at least 2 dispensings of the same medication.  The 
adherence rate observed in this population was 61.3% (N=666), with 70.4% 
(N=765) experiencing no 90 day gaps in therapy.  After adjusting using logistic 
regression, good adherence was associated with documentation of diabetes (OR 
0.691, 95% CI 0.501 - 0.952) or mental health comorbidities (OR 0.587, 95% CI 
0.457 - 0.755).  Poor persistence on therapy was associated with anxiety (OR 
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0.691, 95% CI 0.501 - 0.952) or bipolar disorder (OR 0.587, 95% CI 0.457 - 
0.755). 
Conclusion 
Several factors drive an individual’s adherence and persistence to medication 
regimens.  Adherence and persistence were both decreased in individuals with 
comorbid mental health conditions such as bipolar disorder or anxiety.  
Demographic and employment characteristics were not significant predictors of 
adherence or persistence.
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Background: 
 
Prevalence of Schizophrenia 
 
Treatment of Mental health disorders can be difficult and expensive, and 
these conditions occur fairly commonly in the United States.  The lifetime 
prevalence of schizophrenia is between 0.3% and 1.6%,1 with the period 
prevalence of schizophrenia between 0.13% and 0.82%.2  Although less common 
in commercially insured populations, the prevalence of schizophrenia in that 
group is still not negligible at about 0.13%.3  Despite being less prevalent in the 
commercial population overall, people in this group make up a significant portion 
(16%) of the schizophrenic population.3 
 
Antipsychotic Treatment 
  
Adherence to treatment is a key stumbling block for many patients 
receiving antipsychotics.  A review of the literature by Llorca found that several 
studies demonstrate a significant relationship between low adherence and 
relapses and hospitalization.4  The difficult side effects of antipsychotics, which 
include extrapyramidal effects in first generation antipsychotics and metabolic 
effects in second generation antipsychotics, alone are a barrier to adherence.  A 
study by Bulloch found that 35% of individuals were non-adherent to their 
antipsychotics,5 and Second Generation Antipsychotics were associated with a 
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better likelihood of adherence than First Generation Antipsychotics in several 
studies.6, 7 
Less complicated regimens8, levels of social support,9 and patient attitude 
towards treatment are additional areas associated with patient adherence.10  It 
has also been demonstrated that treatment naïve patients are less likely than 
those who have switched from another medication to be adherent and 
persistent,11 demonstrating the difficulty in selecting a first medication. 
In the schizophrenia population, it is clear that decreased adherence leads 
to a decreased treatment response,12 a higher rate of relapse,13, 14 and greater 
risk of hospitalization.15-17  The Law study in particular found that within 10 days 
of a missed refill, the risk of hospitalization increases significantly.17  In 
schizophrenic patients, adherence was better on second generation 
antipsychotics,18 with Rabinovitch finding that 59.4% of second generation users 
were adherent, compared to 34.5% of first generation users.9  Studies have been 
mixed in their assessment of factors leading to better adherence to 
antipsychotics in the schizophrenic population, with Acosta, et al, finding no 
relationship between sociodemographic, clinical, or treatment related variables 
and adherence,19  while Valenstein et al found that demographic factors such as 
younger age and non-white race were associated with poorer adherence, as 
were clinical factors such as using a second generation antipsychotic.20 
Similar trends emerge among populations of patients having Bipolar 
disorder.  Such patients utilizing second generation antipsychotics were more 
likely to be both adherent and persistent, and also less likely to switch.21  Several 
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studies of patients having bipolar disorder demonstrate a decrease in 
hospitalization risk in adherent groups.22, 23  Bipolar individuals with a medication 
possession ratio (MPR) greater than 80% decreased their risk of hospitalization 
by 18%, compared to those considered non-adherent.23  Barriers such as lacking 
social support also affect adherence in this population.24 
 
Study Purpose and Justification 
 
 There have been many studies conducted to better understand factors 
influencing adherence to antipsychotics.  The vast majority of the literature 
identified above focuses on specific populations with a high incidence of 
schizophrenia, those individuals utilizing Medicaid and Veteran's Administration 
(VA) programs.  The commercial population likely differs significantly from the 
Medicaid and VA groups where patients are typically older, and (especially in the 
VA) more likely to be male.7, 25  This population is also different from those used 
in prospective open-label trials such as CATIE, in which 85% of the population 
was unemployed.26  It is critical to gain a better understanding of medication 
utilization patterns the commercial population.  Sixteen percent of schizophrenic 
patients receive services through private insurance, and represent a fairly 
significant cost in this population.3  Programs designed to better manage these 
populations will utilize the improved information to better understand their 
participants, leading to more targeted interventions.27, 28 
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 In addition to better understanding this population, there are also a wide 
variety of methods utilized to measure adherence to antipsychotics described in 
the literature, although the MPR method is most common.17, 29, 30  MPR and 
proportion of days covered (PDC) have both been shown to be associated with 
poor outcomes such as hospitalization.29  Additionally, evaluating large gaps in 
therapy as a proxy for discontinuation provides insight into longer drug free 
periods and may be associated with different factors than MPR and PDC.17 
 The goal of this analysis was to evaluate factors that may be associated 
with medication adherence among commercially insured patients utilizing 
antipsychotic medications, considering both MPR results and drug 
discontinuation.  These factors include:  the use of first or second generation 
agents, switching treatments, use of combination treatments, and the 
demographic, clinical, and employment characteristics of the population. 
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Methods: 
Study Design: 
 
 Data from the Thompson MarketScan database were utilized to conduct a 
retrospective cohort analysis of medication adherence in the schizophrenic 
population utilizing antipsychotics.  The outcome of interest in this analysis is the 
Medication Possession Ratio (MPR), indicating how closely a patient complies 
with the medication regimen during treatment periods.  The association between 
clinical, demographic, and employment factors on MPR are evaluated based on 
multivariate statistical analysis. 
 
Data Source: 
 
The data source for this analysis is the Thomson MarketScan commercial 
claims dataset, including employees and their dependents working for large 
companies spread across the United States, and insured by roughly 100 different 
payers.  This data set contains comprehensive medical, demographic, and 
employment data for roughly 5.9 million individuals between 2000 and 2001.  The 
data is provided in cleaned data sets, but it was still examined in order to ensure 
that variables were complete and distributed as expected. 
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Inclusion Criteria: 
 
 From the overall eligible population (N = 1,428,349), 2,156 individuals 
(0.15%) were identified as schizophrenic, and 1,361 of those had at least one 
treatment episode where MPR could be calculated.  Inclusion criteria for this 
analysis require that a patient be continuously enrolled for the entire study period 
(24 months), and be between 18 and 65 years of age at the beginning and end of 
the study.  The individuals must also have at least 1 ICD-9 code indicating 
schizophrenia (295.xx), and 2 dispensings for the same antipsychotic medication 
occurring within the period.  Figure II-1 demonstrates the sample selection 
criteria. 
 
Operational Definitions: 
 
Continuous enrollment was defined as having 366 days of continuous 
enrollment in 2000, and 365 days of continuous enrollment in 2001 with both 
medical and pharmacy coverage.  This data was abstracted from the enrollment 
data sets provided.   
Diagnoses for specific conditions were identified through the presence of 
one or more ICD-9 codes in the inpatient or outpatient records.  Anxiety, Bipolar 
Disorder, Depression, Schizophrenia, and Other Mental Health Disorders not 
included above (such as substance abuse) were identified.  Documentation of 
Diabetes was also identified due to the association between second generation 
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antipsychotics and an increased risk of metabolic outcomes.  The specific list of 
ICD-9 codes used to identify these conditions is provided in table II-1.  This 
methodology is similar to that used in a variety of other studies,3, 18, 21, 32 and 
validated by Rawson, et al, in 1997.32 
Therapy with a given treatment was defined as receipt of at least 2 
dispensings of that medication within the study period.  The “therapeutic period” 
for a treatment is the time from the first fill, to the date of the last fill plus the last 
days supply, and any days spent in the hospital.  “Combination Therapy” is 
defined as two treatments overlapping by a minimum of 90 days.  A “switch” in 
therapy was defined as a change from one treatment to another where there is 
no more than a 90 day gap in therapy, and no more than 90 days of overlap in 
therapy.  A discontinuation in treatment is defined as a period of 90 days or more 
without therapy following the end of a therapeutic period, excluding any days in 
the hospital.  Studies have typically used periods of 30 to 90 days to define gaps 
in therapy.18, 21, 33  This study utilized the 90 day period to match the longest days 
supply routinely received by patients. 
Adherence was calculated utilizing the Medication Possession Ratio 
(MPR), calculated utilizing equation 1 below.20  Although a variety of 
methodologies for measuring adherence are available, several methods such as 
electronic monitoring (MEMS caps), or patient questionnaires are not feasible.  
Although electronic monitoring is considered the gold standard,19 use of medical 
records or claims databases are considered more accurate than patient self-
report.19, 34, 35  The decision to use MPR rather than Proportion of Days Covered 
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(PDC) was based on several studies supporting its use,6, 36, 37 as well as it being 
the most common measure reported in the literature, and therefore the best for 
comparison amongst studies.  Any days spent in the hospital were removed from 
the time period between the first and last fills. 
 
Equation 1: 
( )
datefillFirstdatefillLast
qtydaylastqtyday
MPR
____
___
−
−
=
∑
 
 
Therapy duration was calculated as the difference between the end of the 
treatment period and the first fill date, similar to several studies reported in the 
literature.18, 21, 38  One treatment period was identified for each individual based on 
whichever medication, or combination of medications, they were using as of 
January 1, 2001.  Discontinuation was defined as having a therapy end date prior 
to September 30, 2001, and no other antipsychotic treatments between that date 
and the end of the study period. 
Demographic variables were cleaned and defined as well.  An individual’s 
age was defined as the difference between their birth year, and the year 2000.  
There were no instances in the data where an individual had more than 1 gender 
on record.  Employment and geographic variables were defined for each 
individual as the value that turned up most often for that individual (if more than 
one value was available).  Employment characteristics included full time vs. part 
time or unemployed status, primary vs. dependent coverage status, and salary 
vs. hourly pay.  Geographic variables were coded as rural or non-rural based on 
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Metropolitan Statistical Area, and Region (North East, North Central, South, and 
West). 
 
Bivariate analysis 
 
 
Because of the typical left skewed, truncated nature of the distribution of 
MPR, each individual treatment episode was categorized as adherent (MPR 
≥80%) or non-adherent (MPR <80%).  The 80% cut-off has been utilized as the 
threshold in several publications describing adherence rates and outcomes due 
to poor adherence in populations treated for psychiatric conditions including 
schizophrenia.18, 21, 38  Treatment gap of 90 days or more was treated as a 
dichotomous variable.  The relationship between the outcomes of interest 
(adherence and discontinuation) and the clinical and demographic variables (first 
or second generation antipsychotic utilization, treatment combination or switch, 
demographic, and employment variables) was tested using the chi-square 
analysis.  The association between age, the only continuous explanatory 
variable, and adherence and discontinuation was also tested utilizing the 
student's T-test. 
 
Multivariate Analysis: 
 
 Two separate Logistic regression models were used in order to adjust for 
multiple factors influencing MPR and discontinuation.  Adherence to therapy was 
modeled against first or second generation medication choice, switching, 
combination use, demographic, clinical, and employment factors.  Interaction 
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terms including the various combinations of age group, gender, and 
comorbidities were also included if they were associated with the dependent 
variable as measured by the chi-square test with a significant p-value (<0.2).  
Chi-square analysis was also used to assess several potential associations 
amongst independent variables to determine if they were independent.  If the 
variables were not independent (chi-square value was less than 0.05), the less 
important variable was dropped from consideration for the model.  Stepwise 
backwards elimination was used to optimize the model, using the -2 log likelihood 
to test the significance of changes.  Multicollinearity was assessed based on the 
variation inflation factor (VIF), and eignevalues.  These were calculated utilizing a 
separate model with the proc reg function in SAS with the VIF, TOL, and collin 
options.  If the condition number was greater than 30, or the VIF was greater 
than 5, increased scrutiny was given to the affected variables.  Hosmer-
Lemeshow was used to assess goodness of fit. 
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Results: 
Univariate results: 
 
In the first year of data, 2,156 (0.2% of those meeting demographic 
criteria) individuals were identified with at least 1 ICD-9 code indicating 
schizophrenia, of them 1,086 (50.3%) individuals that had at least 2 dispensings 
of the same medication within 90 days of each other to create a treatment 
episode including January 1, 2001.  The demographic, clinical, and employment 
characteristics of the population are described in table II-2.  Of the 1,086 
individuals that had treatments, 666 (61.3%) were considered adherent.  Most of 
the treatment episodes in this analysis were for second generation 
antipsychotics, with 15.1% following a switch in therapies, and 13.8% received in 
combination.  Table II-3 provides a description of the therapies observed in this 
population.   
The mean duration of treatment without any gaps over 90 days between 
January 1, 2000 and December 31, 2001 was 579.2 (sd 173.1) days.  Duration 
had a bimodal distribution due to the short time period of the data, with peaks at 
450 and 750 days (figure II-2).  698 (64.2%) episodes were likely began therapy 
prior to the earliest records in the data, 765 (70.4%) likely continued therapy 
beyond the study period, and 541 (49.8%) were began prior to and ended after 
the study period.  The minority, 164 (15.1%) of episodes occur completely within 
the study period. 
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Bivariate results: 
 
 The bivariate analyses demonstrated that older age was associated with 
greater adherence:  (46.9 [sd 11.3] in the adherent group vs. 45.2 [sd 11.9] in the 
non-adherent group, p=0.014).  Age groupings did not show any statistically 
significant difference in adherence.  Gender was not associated with adherence.  
Patients also having diabetes were significantly less likely to be adherent to 
therapy than non-diabetics (55.0% vs. 62.8% respectively, p=0.042).  Hourly 
workers were more likely than others to be adherent (67.1% vs 59.5% salaried 
and 58.9% others, p=0.0487).   The remaining results are listed in table II-4. 
 Discontinuation was identified in 321 (29.6%) individuals.  These 
individuals tended to be younger, with 18 to 44 year olds discontinuing 33.4% vs 
27.3% in 45 to 64 year olds (p = 0.033).  Individuals with additional mental health 
diagnoses were also significantly more likely to discontinue therapy (36.0% vs 
23.1% [p<0.001] for those with no comorbid mental health conditions 
documented).  Individuals who combined medications (47.3% vs. 26.7% 
[p<0.001] for those that did not combine) or switched between medications 
(37.8% vs. 28.1% [p=0.012] for those that did not switch) were also more likely to 
discontinue therapy.  Table II-5 provides the percent of individuals who 
discontinued and the p-values for all of the variables examined. 
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Multivariate results: 
 
The multivariate analysis found several associations between adherence 
and clinical, demographic, and employment related factors.  Table II-6 provides 
the diagnostic data utilized in fitting the final model.  Adherence was modeled 
against age, gender, comorbid diagnoses, use of a second generation 
antipsychotic, switching, combination use, and payer type.  All variables 
remained in the final model.  This model had a good fit, with c=0.842, and 
Hosmer-Lemeshow p-value = 0.401.  Individuals with a comorbid diagnosis of 
diabetes (OR 0.691, 95% CI 0.501 – 0.952) or other mental health conditions 
such as substance abuse (OR 0.587, 95% CI 0.457 – 0.755) were both less likely 
to be adherent to their antipsychotic treatments.  Other variables did not result in 
significant differences in MPR.  Table II-7 provides the odds ratios associated 
with the remaining variables. 
There were fewer significant associations between discontinuation and the 
demographic, clinical, and employment characteristics tested.  The full model 
included age, gender, diagnosis of anxiety, bipolar disorder, depression, other 
mental health diagnoses,  first or second generation antipsychotic use, switching, 
combination use, and insurance coverage type (primary vs. dependent).   The 
final model included age, gender, comorbid diagnoses, and use of combinations 
(table II-8).  Goodness-of-fit for this model was adequate with c-statistic = 0.747, 
and Hosmer-Lemeshow p-value = 0.495.  Documentation of bipolar disorder (OR 
0.587, 95% CI 0.457 - 0.755) and anxiety (OR 0.691, 95% CI 0.501 - 0.952) were 
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both associated with less likelihood to be persistent.    Table II-9 provides the 
odds ratios from the final model.
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Discussion: 
 
 This analysis demonstrates the importance of comorbidities in the 
likelihood that a patient will be adherent to and persistent on therapy.  Observed 
decreases in adherence associated with a diabetes or other mental health 
diagnoses may lead to treatment being ineffective, with resultant increases in the 
need for medical care, as well as increases in the indirect costs of schizophrenia.  
This analysis gives caregivers, providers, and insurers new insight into the 
factors that increase the risk of non-adherence and non-persistence in the 
commercial population, and these can be utilized to identify the patients who 
would be the best targets for outreach attempting to improve adherence. 
 
Factors Associated with MPR 
 
 Adherence measured by MPR is the most commonly utilized methodology 
in literature addressing claims based studies.  The adherence rate found in our 
study (61.3% of the population having an MPR  above 80%) is higher than that 
seen in other studies, for example Ascher-Svanum found that 58% of participants 
in the US Schizophrenia Care and Assessment Program (US-SCAP) had an 
MPR above 80%, Valenstein found that 60% of the VA population studied had an 
MPR greater than 80%, and Gilmer found that only 41% of the Medicaid 
population they studied was adherent using the same criteria.20, 38, 39  There are a 
number of potential explanations for this finding.  First, studies have shown that 
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social support is a key driver of adherence,9 in this analysis dependents tended 
to be more adherent than primary policy holders, thus dependent status may be 
an indicator of the social support available to these individuals.  In addition to 
differences in the population, there may also be differences in the methodology 
used to calculate MPR, where some studies do not exclude days in the hospital 
from the denominator, or use the entire study period as the denominator, rather 
than just the treatment period. 
 The multivariate results show that certain clinical characteristics are key 
drivers associated with adherence.  There are differing reports on superior 
adherence rates in first vs. second generation antipsychotic users, with a VA 
population having lower adherence to second generation antipsychotics (62.2% 
and 58.8% with an MPR >80% in first vs. second generation antipsychotics 
respectively),20 and a study based on patients with a first episode of psychosis in 
the community found that second generation antipsychotics resulted in better 
adherence (MPR = 59.4% vs. 34.5% in first generation users);6, 9, 20 in the study 
described here, we found that there was no significant difference in adherence 
for second generation antipsychotic users as compared to first generation 
antipsychotic users.   
Individuals with other mental health disorders also had lower adherence rates, 
which correlate with the existing literature.40  A study by Lang et al found that 
combination users were more likely to be adherent than those using single 
treatments (71% in combination users vs. 70% in first generation users and 64% 
in second generation users), agreeing with our study that found that combination 
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users trended towards higher adherence than single medication users (OR 
1.361, 95% CI 0.939 - 1.972).40  There was also lower adherence among patients 
having diabetes in our study, which may be indicative of concern about metabolic 
adverse events, or associated with increased complexity of care in general.41  
Other studies have also found limited associations between demographic, 
economic / work, and clinical variables and adherence.19 
 
Factors Associated with Persistence 
 
 Persistence indicates the length of time an individual is able to remain on 
treatment.  Due to the relatively short timeframe available for this study, most 
individuals were already on a treatment at the beginning of the study, and still 
taking it at the end.  Therefore we were unable to calculate a true estimation of 
treatment duration in this population, but with nearly 50% of the population 
receiving therapy without more than a 90 day gap at the beginning and end of the 
study, the commercially insured population performs significantly better than the 
CATIE population, where 74% of new users discontinued therapy by 18 
months,26 as well as a VA population where the median time to discontinuation 
was 120 days.33 Being persistent on therapy is crucial as the risk for poor 
outcomes such as hospitalization can begin to increase in as little as 10 days 
after discontinuing therapy.17 
 Our study demonstrated an increased risk for discontinuation in 
populations with comorbid bipolar disorder or anxiety.  These conditions likely 
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complicate therapeutic regimens due to their episodic nature, leading to 
discontinuations due to changes in overall disease states, but also due to 
confusion on the part of the individual.8  Overall, there were very few variables 
associated with discontinuation following adjustment with logistic regression.  
This is in agreement with the literature where Gianfrancesco et al found that 
there was no difference in persistence between first and second generation 
antipsychotics in a commercial population.18  In an evaluation of the VA 
population, there was less likelihood of discontinuation in second generation 
antipsychotic users as compared to first generation antipsychotic users.  Several 
issues may be causing this difference in outcomes.  First, the VA study did not 
control for comorbid conditions in their analysis.  Additionally there are some 
substantial differences in the populations, with the VA consisting largely of older 
male patients at the time, and the Medicaid population likely having significant 
differences in sociodemographic characteristics such as income and social 
support that could not be measured in either study. 
 
Limitations 
 
 Studies utilizing claims records to measure adherence are prone to 
several well documented limitations.  For instance, without observing an 
individual taking a medication one cannot be sure that it is being taken.  
Pharmacy claims can also be incomplete if patients receive samples from their 
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physician, or pay cash rather than their copay for inexpensive generics, resulting 
in underestimates of adherence. 
 The short time period available in our data also limited the ability to follow 
patients over a long period of time based on trade-offs with population size.  
Future studies using a broader population, and longer timeframe may also be 
able to identify more significant drivers of adherence and persistence than those 
seen in our population.  The age of this data may also limit generalizability due to 
the addition of new treatments and changes in guidelines over time.  
Generalizability is also limited to the commercially insured population 
represented by the data. 
The limitations of claims data might also help to explain why full time 
workers are less likely to be adherent to therapy.  Although our methodology for 
identifying schizophrenia in the population is in line with several other published 
studies,3, 18, 32 requiring only one ICD-9 code for schizophrenia may be allowing 
some false positives.  Although uncommon (Rawson et al found 97% agreement 
between computerized records and medical charts),32 if those false positives are 
represented disproportionately in full time workers, it might be the case that those 
individuals are more likely to be using these antipsychotics for off-label 
purposes,42 such as the use of low dose quetiapine for sleep, which in turn could 
be lowering their overall possession ratios.  Further research to validate the 
coding of schizophrenia in commercial databases would be necessary to confirm 
or reject this hypothesis. 
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Conclusions 
 
 Several factors drive an individual’s adherence and persistence to 
medication regimens.  Adherence and persistence were both decreased in 
individuals with comorbid bipolar disorder or anxiety.  Demographic and 
employment characteristics were not significant predictors of adherence or 
persistence.
 65 
Figures: 
Figure II-1:  Inclusion and exclusion criteria flowchart 
 
MarketScan Population: 
5,829,954 
Exclude: Less than 24 months  
continuous enrollment: 
3,887,128 (66.7%) 
Exclude: Less than 18 years of age: 
505,864 (8.7%) 
Exclude: Over 65 years of age: 
8,613 (0.1%) 
Population Meeting Demographic Criteria: 
N = 1,428,349 (24.5%) 
Individuals with >=1 ICD code for Schizophrenia: 
N = 2,156 (0.2%) 
Rx Treated Schizophrenic Population 
on 1/1/2001  
(at least 2 fills of the same medication) 
N = 1,086 (0.1%) 
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Figure II-2:  Histogram of frequency of days of continual antipsychotic treatment 
among patients with a diagnosis of schizophrenia 
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Tables: 
 
Table II-1:  ICD-9 Codes used for identifying diagnoses with 
primary conditions and comorbidities 
Condition ICD-9 Codes Included 
Schizophrenia 295 - 295.95 
Bipolar Disorder 296 - 296.99 
Anxiety 300 - 300.09 
Depression 311, 300.4 
Other Mental Health 290 - 319, except for those listed above 
Diabetes 250.00 – 250.99 
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Table II-2:  Demographic characteristics of the study population 
  
Total                                           
(N = 1086) 
    N % of Total 
Age 18 - 44 401 36.9 
45 - 64 685 63.1 
Gender Male 441 40.6 
Female 645 59.4 
Location Rural 203 18.7 
Non-Rural 883 81.3 
North East 306 28.2 
North Central 306 28.2 
South 427 39.3 
West 47 4.3 
Diagnoses Bipolar Disorder 333 30.7 
No Bipolar Disorder 753 69.3 
Anxiety 107 9.9 
No Anxiety 979 90.1 
Depression 239 22.0 
No Depression 847 78.0 
Other Mental Health 545 50.2 
No Other Mental Health 541 49.8 
Diabetes 200 18.4 
No Diabetes 886 81.6 
Medication 
Utilization 
Second Generation 
Antipsychotic 710 65.4 
First Generation Antipsychotic 282 26.0 
Both (combination) 94 8.7 
Switched To 164 15.1 
Not post switch 913 84.1 
Combined 150 13.8 
Not Combined 936 86.2 
Employment Full Time 569 52.4 
Part Time / Retired / 
Unemployed 517 47.6 
Primary Policy Holder 527 48.5 
Dependent 559 51.5 
Salary 227 20.9 
Hourly 307 28.3 
No Pay / Unknown 552 50.8 
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Table II-3:  Treatments observed in the study population 
  
N % 
Total Population 1086 100.0% 
Second 
Generation 
Antipsychotics 
Any SGA monotherapy 665 61.2% 
Clozapine (Clozaril) 60 5.5% 
Risperidone (Risperdal) 251 23.1% 
Quetiapine (Seroquel) 85 7.8% 
Olanzapine (Zyprexa) 269 24.8% 
First 
Generation 
Antipsychotics 
Any FGA monotherapy 271 25.0% 
Haloperidol (Haldol) 49 4.5% 
Loxipine (Loxitane) 13 1.2% 
Thioridazine (Mellaril) 31 2.9% 
Molindone (Mobane) 3 0.3% 
Thiothixene (Navane) 39 3.6% 
Pimozide (Orap) 2 0.2% 
Fluphenazine (Prolixin) 30 2.8% 
Mesoridazine (Serentil) 3 0.3% 
Trifluoperazine (Stelazine) 46 4.2% 
Chlorpromazine (Thorazine) 19 1.7% 
Perphenazine (Trilafon) 36 3.3% 
Combinations Any Combination 150 13.8% 
2 or more Second Generations 45 4.1% 
2 or more First Generations 11 1.0% 
First and Second Generation 94 8.7% 
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Table II-4:  Bivariate associations between adherence and demographic, clinical, 
and employment characteristics  
  
Adherent                  
(N=666) 
Non-Adherent            
(N = 420) 
p-value 
    N % Adherent N 
% Non-
Adherent 
Age 18 - 44 238 59.4 163 40.6 0.3067 
45 - 64 428 62.5 257 37.5 
Gender Male 266 60.3 175 39.7 0.573 
Female 400 62.0 245 38.0 
Location Rural 120 59.1 83 40.9 0.473 
Non-Rural 546 61.8 337 38.2 
North East 195 63.7 111 36.3 
0.726 North Central 183 59.8 123 40.2 South 258 60.4 169 39.6 
West 30 63.8 17 36.2 
Diagnoses Bipolar Disorder 200 60.1 133 39.9 0.569 
No Bipolar Disorder 466 61.9 287 38.1 
Anxiety 60 56.1 47 43.9 0.240 
No Anxiety 606 61.9 373 38.1 
Depression 140 58.6 99 41.4 0.323 
No Depression 526 62.1 321 37.9 
Other Mental Health 298 54.7 247 45.3 
<0.001 No Other Mental 
Health 368 68.0 173 32.0 
Diabetes 110 55.0 90 45.0 0.042 
No Diabetes 330 37.2 556 62.8 
Medication 
Utilization 
Second Generation 
Antipsychotic 433 61.0 277 39.0 
0.2435 First Generation 
Antipsychotic 168 59.6 114 40.4 
Both (combination) 65 69.1 29 30.9 
Switched To 90 54.9 74 45.1 0.066 
Not post switch 567 62.1 346 37.9 
Combined 101 67.3 49 32.7 0.104 
Not Combined 565 60.4 371 39.6 
Employment Full Time 339 59.6 230 40.4 
0.215 Part Time / Retired / 
Unemployed 327 63.2 190 36.8 
Primary Policy 
Holder 316 60.0 211 40.0 0.370 
Dependent 350 62.6 209 37.4 
Salary 135 59.5 92 40.5 
0.049 Hourly 206 67.1 101 32.9 
No Pay / Unknown 325 58.9 227 41.1 
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Table II-5:  Bivariate associations between discontinuation and demographic, 
clinical, and employment characteristics  
 
  
No Discontinuation           
(N = 765) 
Discontinued                       
(N = 321) 
p-value 
    N % N % 
Age 18 - 44 267 66.6 134 33.4 0.033 
45 - 64 498 72.7 187 27.3 
Gender Male 313 71.0 128 29.0 
0.7502 Female 452 70.1 193 29.9 
Location Rural 140 69.0 63 31.0 0.609 
Non-Rural 625 70.8 258 29.2 
North East 213 69.6 93 30.4 
0.329 North Central 225 73.5 81 26.5 South 291 68.1 136 31.9 
West 36 76.6 11 23.4 
Diagnoses Bipolar Disorder 211 63.4 122 36.6 
0.001 No Bipolar 
Disorder 554 73.6 199 26.4 
Anxiety 58 54.2 49 45.8 0.000 
No Anxiety 707 72.2 272 27.8 
Depression 145 60.7 94 39.3 0.000 
No Depression 620 73.2 227 26.8 
Other Mental 
Health 349 64.0 196 36.0 
<0.0001 No Other Mental 
Health 416 76.9 125 23.1 
Diabetes 146 73.0 54 27.0 0.380 
No Diabetes 619 69.9 267 30.1 
Medication 
Utilization 
Second 
Generation 
Antipsychotic 
505 71.1 205 28.9 
0.000 First Generation 
Antipsychotic 211 74.8 71 25.2 
Both (combination) 49 52.1 45 47.9 
Switched To 102 62.2 62 37.8 0.012 
Not post switch 663 71.9 259 28.1 
Combined 79 52.7 71 47.3 
<0.0001 
Not Combined 686 73.3 250 26.7 
Employment Full Time 408 71.7 161 28.3 
0.339 Part Time / Retired 
/ Unemployed 358 69.1 160 30.9 
Primary Policy 
Holder 381 72.3 146 27.7 0.194 
Dependent 384 68.7 175 31.3 
Salary 163 71.8 64 28.2 
0.472 Hourly 208 67.8 99 32.2 
No Pay / Unknown 394 71.4 158 28.6 
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Table II-6:  Logistic regression model optimization for factors associated with 
adherence 
Iteration Description 
Log 
Likelihood 
Difference 
in -2 Log 
Likelihood 
Model 
DF 
x2 
critical 
value P-value 
1 Full Model* ** 1416.211   9     
2 Full Model - Pay Type 1418.950 5.478 8 3.84 <0.05 
*Full model Includes:  Age, gender, diagnoses, use of a second generation antipsychotic, 
switching, combination, insurance coverage, and full time employment 
**Final model includes all variables from the full model 
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Table II-7:  Odds ratios for the likelihood that an individual will be  
adherent to treatment 
 
 
Point 
Estimate 95%Confidence Limits 
Demographic Male vs. female 0.919 0.712 1.187 
Age 45-64 vs.  
18-44 1.11 0.849 1.451 
 Clinical Other Mental 
Health vs. none 0.587 0.457 0.755 
Diabetes vs. no 
diabetes 0.691 0.501 0.952 
Switch vs. no 
switch 0.806 0.572 1.137 
Combination vs. 
no combination 1.361 0.939 1.972 
Employment Salary vs. Hourly 
Wages 0.903 0.664 1.228 
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Table II-8:  Logistic regression model optimization for factors associated with 
discontinuation 
Iteration Description 
Log 
Likelihood 
Difference 
in -2 Log 
Likelihood 
Model 
DF 
x2 
critical 
value P-value 
1 Full Model* 1244.158   11     
2 
Full Model - 
Antipsych Type 1244.56 0.804 9 3.84 >0.05 
3 
Full Model - 
Antipsych 
Type,Insurance 1245.14 1.16 8 3.84 >0.05 
4 
Full Model - 
Antipsych Type, 
Insurance, Switch** 1246.541 2.802 7 3.84 >0.05 
5 
Full Model - 
Antipsychotic Type, 
Insurance, Switch, 
Anxiety 1249.458 5.834 6 3.84 <0.05 
* Full model Includes:  Age, gender, diagnoses, use of a second generation antipsychotic, 
switching, combination, and insurance coverage type 
**The final model includes all variables from the full model except use of a second 
generation antipsychotic, insurance coverage type, and switching 
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Table II-9:  Odds ratios for the likelihood that an individual will be  
persistent on treatment 
  
  Point 
Estimate 
95%Confidence Limits 
Demographic Male vs. female 1.042 0.787 1.381 
Age 45-64 vs 18-
44 1.222 0.922 1.619 
Clinical Bipolar vs. no 
bipolar 0.587 0.457 0.755 
Anxiety vs. no 
anxiety 0.691 0.501 0.952 
Depression vs. 
no depression 0.806 0.572 1.137 
other mental 
health diagnosis 
vs. none 
1.361 0.939 1.972 
Combination vs. 
monotherapy 0.903 0.664 1.228 
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CHAPTER 3 
 
ASSOCIATION BETWEEN ADHERENCE AND HOSPITALIZATION IN A 
COMMERCIALLY INSURED POPULATION RECEIVING ANTIPSYCHOTICS 
 
Formatted for submission to the Journal of Managed Care Pharmacy 
(JMCP), not yet submitted. 
 81 
Abstract 
Background 
Adherence to treatments for schizophrenia are associated with significant 
adverse events that often lead to poor adherence and discontinuation of therapy.  
The lack of adherence to therapy may limit its effectiveness and be associated 
with poor outcomes.  The purpose of this analysis is to determine if there is a 
significant difference in mental health associated hospitalization rates for those 
individuals with high adherence as compared to those with lower rates of 
adherence. 
Methods 
This study utilized a matched retrospective cohort design.  Data were obtained 
from the MarketScan database between 2000 and 2001, and included 1,361 
schizophrenia patients treated with antipsychotics.  Propensity score matching 
was utilized to control for differences in sociodemographic and clinical factors 
between the adherent and non-adherent populations.  Adherence was defined 
based on the Medication Possession Ratio (MPR) being greater than or equal to 
80%. 
Results 
Matching was successful in selecting a non-adherent comparison group for 
76.5% of the adherent population, with significant support across the full range of 
propensity scores.  The matching process was successful in limiting the 
differences in demographic and clinical characteristics between the groups.  The 
risk of hospitalization was higher in the non-adherent population (RR 1.55, 95% 
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CI 1.07 – 2.25) than the adherent population after matching.  This is slightly lower 
than the relative risk seen in the unmatched group (RR 1.74, 95% CI 1.22 – 2.49 
in the adherent population vs. the non-adherent population). 
 
Conclusion 
 
Adherence to antipsychotic treatment has a significant association with a lower 
likelihood of hospitalization in the schizophrenia population.  Additional analysis 
is necessary to understand the impact of persistence, and other medication 
taking behaviors such as switching or polytherapy. 
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Background 
Schizophrenia 
 
Mental health disorders are prevalent in the United States, and treating 
these conditions can be difficult and expensive.  A study conducted by Kessler, 
et al, found that the lifetime prevalence of schizophrenia is between 0.3% and 
1.6%.1  A systematic review of the literature found that the period prevalence of 
schizophrenia is between 0.13% and 0.82%.2  An evaluation of a commercially 
insured population found that the prevalence of schizophrenia in that group is 
near the lower end of the range, at about 0.13%.3  Despite being less prevalent 
in the commercial population, people in this group make up a significant portion 
(16%) of the schizophrenic population.3 
 
Treatments and Adherence  
 
Adherence to treatment is a key stumbling block for many patients 
receiving antipsychotics.  It can take up to 16 weeks for a treatment regimen to 
become effective for relieving symptoms, but adverse events can occur far 
earlier.4  A review of the literature by Llorca found that several studies 
demonstrate a significant relationship between low adherence and poor 
outcomes. 5  The side effects of antipsychotics alone are a barrier to adherence.  
These adverse events are largely metabolic for second generation 
antipsychotics, while first generation antipsychotics are associated with 
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extrapyramidal side effects.  A study by Bulloch found that 35% of individuals 
were non-adherent to their antipsychotics, 6 and second generation 
antipsychotics were associated with a better likelihood of adherence than first 
generation antipsychotics in several studies.7, 8 
Less complicated regimens, 9 levels of social support, 10 and patient 
attitude towards treatment are additional areas associated with improved patient 
adherence. 11  It has also been demonstrated that treatment naïve patients are 
less likely than those who have switched from another medication to be adherent 
and persistent, 12 demonstrating the difficulty in selecting a first medication. 
Adherence rates in the literature vary substantially depending on the 
population, and methods used to measure it.  The medication possession ratio 
(MPR) is based on the sum of the days supply divided by the duration of therapy, 
whereas the proportion of days covered (PDC) is the number of days with 
therapy available divided by the length of the study.13  Individuals with a 
diagnosis of schizophrenia and a medication possession ratio (MPR) greater 
than 80% range between 35% and 60%,6, 14-17 coincidentally, the average MPR 
or PDC also ranged between 35% and 60% in different studies.8, 10  This 
demonstrates the importance of ensuring that results are interpreted with 
population differences in mind, as results from one group may not be 
generalizable to another. 
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Impact of Poor Adherence 
 
Non-adherence to medications leads increasingly poor outcomes over 
time.5  Poor adherence is a key driver of relapses in schizophrenia, leading to 
costs that are 3 times higher than non-relapsers.18  One key driver of this cost is 
hospitalization.  A Canadian study in 2006 found that individuals who had a 
medication possession ratio (MPR) of greater than 80% had 63% fewer 
hospitalizations.19  A Medicaid population in Wisconsin had twice as many 
hospitalizations in the non-adherent group, and costs were 4 times higher.20  The 
risk of hospitalization increases quickly following discontinuation, with a study by 
Law et.al. observing the risk increase in as little as 10 days.21   
Medication therapy choice regarding switching, combination therapy, and 
use of first vs. second generation antipsychotics might also impact hospitalization 
rates.  In a Medicare population, second generation antipsychotic users and 
those on combination therapy were more likely to be hospitalized as compared 
with those utilizing first generation antipsychotics without combining, although the 
impact of adherence was not addressed in this analysis.22   
 
Study Purpose and Justification 
 
 It has been estimated that hospitalizations could be decreased by 12.3% 
in the Medicaid population, saving $103 million per year in the United States if 
gaps in therapy of longer than 15 days could be eliminated.23  Interventions have 
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been successful in improving adherence rates, but additional information 
regarding the causes of adherence, and the populations where non-adherence is 
most likely could make these programs more effective.24  A key to making this 
information useful is ensuring that it is generalizable to the population where 
these programs are implemented. 
 There have been many studies conducted to better understand the factors 
leading to hospitalizations in the schizophrenia population.  The vast majority of 
the literature identified above focuses on specific populations with a high 
incidence of schizophrenia, those individuals utilizing Medicaid and VA programs.  
The commercial population likely differs significantly from the Medicaid and VA 
groups where patients are typically older, and (especially in the VA) more likely to 
be male.22, 23, 25  This population is also different from that identified in Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE), a prospective 
comparative effectiveness trial, in which 85% of the population was unemployed. 
26
  A better understanding of medication use within the commercial population is 
critical.  Sixteen percent of schizophrenics receive services through private 
insurance, and represent a fairly significant cost in this population. 3 
The purpose of this study is to determine the association between 
adherence to antipsychotics and decreased rates of hospitalization, while 
controlling for other medication taking behaviors and patient characteristics that 
could be associated with increased hospitalization rates in the commercially 
insured population receiving antipsychotics. 
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Methods 
 
Study Design 
 
A matched retrospective cohort study was conducted.  Individuals who 
were adherent to antipsychotics were matched to non-adherent individuals based 
on propensity scores measuring the likelihood of adherence to medication.  
Medication taking characteristics were examined for 1 year prior to the admission 
date of the hospitalized patient and in their non-hospitalized match. 
 
Data 
 
Data for this analysis was made available through the Thomson Medstat 
dissertation support program.  This program provides access to de-identified data 
in the MarketScan database from years 2000 and 2001.  This database contains 
enrollment and demographics data, as well as medical and pharmacy claims for 
nearly 5.9 million individuals. 
 
Inclusion Criteria 
 
 Individuals were considered for inclusion in this study if they have at least 
1 ICD-9 code indicating schizophrenia, 24 months of continuous enrollment, at 
least 2 fills of an antipsychotic medication in year 1, and are between 18 and 64 
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years old in the year 2000.  Individuals were excluded if they were hospitalized 
for a mental health condition any time during the first year of the study.  Figure 
III-1 describes the inclusion waterfall. 
 
Operational Definitions 
 
Operational definitions have largely been carried over from the work done 
previously to describe the antipsychotic using population.  Continuous enrollment 
was defined as having 366 days of continuous enrollment in 2000, and 365 days 
of continuous enrollment in 2001 with both medical and pharmacy coverage.  
This data was abstracted from the enrollment data sets provided.   
Hospitalizations were based on those individuals hospitalized for a mental 
health condition as defined by any inpatient record with a Major Diagnostic 
Category of 19, indicating treatment was for “Mental Diseases and Disorders.”  
The hospitalization date was based on the related first hospital admission in 
2001.  Non-hospitalized patients were any individuals that did not have any 
hospitalizations for a mental health condition as defined above during the study 
period. 
Diagnoses for specific conditions were identified through the presence of 
ICD-9 codes in the inpatient or outpatient records.  Anxiety, Bipolar Disorder, 
Depression, Schizophrenia, Other Mental Health Disorders not included above, 
and Diabetes were all identified.  The specific list of ICD-9 codes used to identify 
these conditions is provided in table III-1.  The use of documentation of ICD-9 
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codes to identify schizophrenia and comorbidities matches the methodology used 
in a variety of other studies, 3, 27, 28 and is similar to methodology utilizing 
hospitalization billing records validated by Rawson, et al, in 1997. 29 
Therapy with a given treatment was defined as receipt of at least 2 fills 
within the study period.  The “therapeutic period” for a treatment is the time from 
the first fill, to the date of the last fill plus the last days supply.  “Combination 
Therapy” is defined as two treatments overlapping by a minimum of 90 days.  A 
“switch” in therapy is defined as a change from one treatment to another where 
there is no more than a 90 day gap in therapy, and no more than 90 days of 
overlap in therapy.  A “gap” in treatment is defined as a period of 90 days or 
more following the end of a therapeutic period, plus any days in the hospital (for 
non-mental health reasons).  Studies have typically used periods of 30 to 90 
days to define gaps in therapy 27, 28, 30.  This study utilized the 90 day period to 
match the longest days supply likely to be received by patients. 
Demographic variables were cleaned and defined as well.  Individual’s 
age was defined as the difference between their birth year, and the year 2000.  
There were no instances in the data where an individual had more than 1 gender 
on record.  Employment and geographic variables were defined for each 
individual as the value that turned up most often for that individual (if more than 
one value was available). 
Adherence was calculated utilizing the Medication Possession Ratio 
(MPR), calculated utilizing equation 1 below.  Although a variety of 
methodologies for measuring adherence are available, several such as electronic 
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monitoring (MEMS caps), or patient questionnaires are not feasible.  Although 
electronic monitoring is considered the gold standard 17, use of medical records 
or claims databases are considered more accurate than patient self-report. 17, 31, 
32
  The decision to use MPR rather than Proportion of Days Covered (PDC) was 
based on several studies supporting its use,7, 13, 33, 34 as well as it being the most 
common measure reported in the literature, and therefore the best for 
comparison amongst studies.  Individuals were defined as adherent to therapy if 
their MPR was above 80%. 
 
Equation 1: 
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∑
 
 
Propensity Scores 
 
 Propensity scores were developed for the likelihood that a patient will be 
adherent given their demographic, clinical, and employment characteristics (see 
table III-2 for a list of specific variables).  Chi-square analysis was conducted in 
order to identify key characteristics based on a p-value greater than 0.2.  The full 
logistic regression model was then optimized using backwards stepwise 
regression.  The log-likelihood test was used to determine if there were 
significant differences in the models.  Correlations were utilized to identify risk of 
collinearity, and the Hosmer-Lemeshow test was used to assess goodness-of-fit. 
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Matching and Statistical Analysis 
 
Individuals with an MPR greater than 80% were matched 1:1 to non-
adherent individuals based on the propensity scores.  A nearest neighbor 
matching algorithm was used, utilizing calipers set to ½ of a standard deviation of 
the propensity scores.  Standardized differences were used to assess balance in 
variables before and after matching.  This methodology is the same at that used 
by Bangelore et. al. 35 in their analysis of the impact of beta-blocker use on 
clinical outcomes.   The difference in hospitalization risk between adherent and 
non-adherent individuals was also assessed using the Chi-square test.  Logistic 
regression was also utilized to control for factors differing between the 
hospitalized and non-hospitalized populations following matching.  This model 
was optimized and tested in the same manner as the propensity score models 
described above.
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Results 
Population: 
 
 This population examined in this study is described in table III-2.  The 
mean age of the population was higher in the pre-match population than the 
post-match population (46.7 vs. 46.3) prior to matching, but the difference was 
not clinically significant.  The population contained fewer males both before and 
after matching (41.2% pre, 39.9% post).  The percent of individuals living in rural 
areas increased slightly from 19.1% to 19.6%, with a slight increase in the 
proportion of individuals living in the South and West.  There were also slight 
increases in the number of full time and salaried workers.  The number of 
individuals with other mental health conditions increased by about 4.2%, but 
other comorbidities remained similar.  Overall, the matched group is 
representative of the population from which it was produced. 
 
Propensity Scores:  
 
 The propensity score model was successfully optimized (see table III-3) 
based on changes in -2 log likelihood.  Goodness-of-fit was adequate based on a 
c-statistic = 0.782, and Hosmer-Lemeshow p-value = 0.482.  The key drivers of 
adherence based on this model were age, gender, region, anxiety, other mental 
health diagnoses, diabetes, full time employment, and salary vs. hourly pay.  
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There was support for matching adherent to non-adherent individuals across 
nearly the full range of assigned propensity scores (see figure III-2). 
 
Matching: 
 
 Matching was successful in limiting the differences in key variables 
associated with adherence between the adherent and non-adherent populations.  
A match was identified for 76.5% of the adherent individuals, utilizing 91.6% of 
the non-adherent individuals.  Figure III-3 describes the standardized differences 
in key variables before and after matching. 
 Prior to matching, age was significantly higher in the adherent population 
than the non-adherent population (47.7 vs. 45.5, p-0.002), but after matching the 
difference was no longer statistically significant (45.8 vs 46.9, p-0.169 in the 
adherent and non-adherent groups respectively).  Differences between the 
adherent and non-adherent populations based on gender remained insignificant 
at the alpha = 0.05 level, as was the case for location and most of the 
comorbidities evaluated.  There was a statistically significant difference before 
matching in other mental health disorders, which did not exist following matching.  
The variables that were significant at the alpha = 0.2 level prior to matching were 
also no longer significant after matching.  Table III-2 provides the details of these 
results.  The details of the model fitting procedure are provided in table III-3. 
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Impact of Adherence on Hospitalization: 
 
 The impact of adherence on hospitalization rates was apparent in the 
unmatched population, as well as the matched only and matched and statistically 
controlled groups.  The relative risk of hospitalization in the matched non-
adherent group was 55% higher than in the adherent population (RR 1.55, 95% 
CI 1.07 - 2.25).  In the unmatched population, the relative risk of hospitalization in 
the non-adherent group was 74% higher than in the adherent population (RR 
1.7441, 95% CI 1.22 - 2.49).  Hospitalization rates in each group are described in 
table III-4. 
 There were also significant differences in a variety of clinical, 
demographic, and employment characteristics between hospitalized and non-
hospitalized individuals both before and after matching.  Table III-5 describes 
these characteristics in the hospitalized and non-hospitalized populations before 
and after matching.  The strongest drivers of hospitalization in addition to 
adherence in both cases were comorbid bipolar disorder, anxiety, depression, 
and other mental health conditions, and therapy characteristics including choice 
of first vs. second generation antipsychotic, switching, and combination use. 
 After controlling for confounders using logistic regression, adherence was 
still a significant predictor of hospitalization avoidance (OR 0.627, 95% CI 0.394 - 
0.999).  Individuals with bipolar disorder, depression, and other mental health 
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conditions also had significantly higher rates of hospitalization. See table III-6 for 
model diagnostics, and table III-7 for odds ratios generated by the logistic model.  
The difference in hospitalization rates between users of first and second 
generation antipsychotics were not significant, but those who used combinations 
or switched therapies were significantly more likely to be hospitalized.  Table III-8 
describes the differences in hospitalization rates between the matched and un-
matched populations, and table III-9 describes the differences in odds ratios 
between methods. 
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Discussion: 
 
 Poor adherence is a significant predictor of increased hospitalization risk 
for individuals with schizophrenia.  This analysis clarifies the risk of non-
adherence to therapy in a commercially insured population, and provides a clear 
incentive for patients, providers, caregivers, and insurers to ensure that those 
patients receiving antipsychotics remain true to their regimen.  Identifying those 
individuals at risk for non-adherence and ensuring they are receiving support to 
overcome their barriers to adherence could lead to significantly lower numbers of 
hospitalizations, which in turn could lead to lower costs and essentially pay for 
the support programs. 
 
Impact of adherence on hospitalizations 
 
 A variety of studies have looked at the association between adherence 
and hospitalizations due to mental health disorders, and many of them have 
found that hospitalization rates were nearly reduced by half between those who 
were adherent and those who were not.19, 20, 36  This study found a more modest 
difference in hospitalization rates, with a relative risk of hospitalization of 1.55 
(95% CI 1.07 – 2.25) in the non-adherent population, as compared to adherent 
populations.  Although adherence to medication is an important factor in avoiding 
hospitalizations, several other key factors emerged as well, with comorbidities, 
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polypharmacy, and treatment switches increasing the likelihood of 
hospitalization.  
 The hospitalization rates seen in this population are below those seen in 
Medicaid populations20 (42% in the Medicaid non-adherent population vs. 14.5% 
in the commercial non-adherent population).  This reinforces the need for 
population specific studies, as the severity of disease in this population is 
significantly lower as measured by hospitalizations. 
 
Meaning of different methodologies 
  
 The importance of properly controlling comorbidities was also evident after 
examining the results of this analysis.  Although the same conclusion holds 
throughout the unmatched, matched, and matched with logistic regression 
analyses, the magnitude of the impact decreases significantly with stronger 
controls for selection bias and potential confounders.  Many of the studies 
performed in the literature did not control as carefully for these biases, and may 
be over-estimating the impact of adherence on hospitalization rates.  Although 
adherence is important in avoiding hospitalizations, inflating the impact may 
divert limited funds from managed care outreach programs that address 
polypharmacy and other therapeutic issues to those focused more directly on 
adherence.  In the end, it would be ideal to address all of a patient’s medication 
taking behaviors, but the statistical analysis in this study shows that getting 
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people settled on a suitable monotherapeutic regimen might result in a lower rate 
of hospitalizations. 
 
Limitations 
 
 This study is limited to inferences that can be made from claims 
databases.  A matched cohort study cannot be used to assess causality, 
although every attempt was made to address potential confounders, issues 
known to impact adherence and risk of hospitalization such as social support and 
disease severity could not be observed based on claims data.  The limited 
timeframe of the study also made it difficult to assess the impact of persistence 
on outcomes.  Users of depot medications were excluded from the study, 
potentially eliminating individuals with more severe, or long-term illness.  The age 
of the data utilized in this study may also lead to limited generalizability due to 
changes in available therapies and differences in guidelines.  The results are 
also limited in generalizability to the commercially insured population, and differ 
significantly for similar studies of Medicare, Medicaid, and Veterans populations. 
 Studies utilizing claims records to measure adherence are prone to 
several well documented limitations.  For instance, without observing an 
individual taking a medication one cannot be sure that it is being taken.  
Pharmacy claims can also be incomplete if patients receive samples from their 
physician, or pay cash rather than their copay for inexpensive generics, resulting 
in underestimates of adherence.  Severity of illness is also a confounder that is 
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difficult to control for based on claims data, but may have biased the results if 
individuals with more severe disease were also less likely to be adherent to 
therapy.   
 
Conclusions 
 
Regardless of methodology, there risk of hospitalization increases 
substantially if individuals are not adherent to therapy as prescribed.  Although 
adherence is a significant issue, polypharmacy and switching between 
treatments are also closely tied to hospitalization, and future studies should 
assess their impact.
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Figures: 
Figure III-1:  Inclusion and exclusion criteria flowchart 
 
MarketScan Population: 
5,829,954 
Exclude: Less than 24 months  
continuous enrollment: 
3,887,128 (66.7%) 
Exclude: Less than 18 years of age: 
505,864 (8.7%) 
Exclude: Over 65 years of age: 
8,613 (1.5%) 
Population Meeting Demographic Criteria: 
N = 1,428,349 (24.5%) 
Individuals with >=1 ICD code for Schizophrenia: 
N = 2,156 (0.2%) 
Rx Treated Schizophrenic Population  
(at least 2 fills of the same medication in year 1) 
N = 1,361 (0.1%) 
Exclude:  Hospitalization in Year 1:  
337 (24.8% of treated population) 
Adherent in Year 2 
N = 558 (41.0% of 
treated population) 
Non-Adherent in Year 2 
N = 466 (32.8% of treated 
population) 
Matched Adherent in 
Year 2 
N = 427 (76.5% of 
adherent population) 
Matched Non-Adherent in 
Year 2 
N = 427 (91.6% of non-
adherent population) 
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Figure III-2:  Matching support for propensity scores in adherent vs. non-
adherent populations 
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Figure III-3:  Absolute standardized differences in matched variables before and 
after matching 
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Tables: 
 
Table III-1:  ICD-9 Codes used for identifying diagnoses with 
primary conditions and comorbidities 
Condition ICD-9 Codes Included 
Schizophrenia 295 - 295.95 
Bipolar Disorder 296 - 296.99 
Anxiety 300 - 300.09 
Depression 311, 300.4 
Other Mental Health 290 - 319, except for those listed above 
Diabetes 250.00 – 250.99 
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Table III-2:  Bivariate analysis of clinical, demographic, and employment factors 
potentially associated with adherence before and after matching 
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Table III-3:  Model fitting diagnostics for propensity score, modeling likelihood 
of hospitalization among adherent and non-adherent groups, controlling for 
other covariates.  
Iteration Description 
Log 
Likelihood 
Difference 
in -2 Log 
Likelihood 
Model 
DF 
critical 
value 
(x2) P-value 
1 Full Model* 1376.41   11     
2 
Full Model 
- Rural** 1377.705 2.59 10 3.84 >0.05 
3 
Full Model 
- Rural, 
Anxiety 
1379.704 3.998 9 3.84 <0.05 
*Full model Includes:  Age, gender, rural, region, anxiety, other mental health 
diagnosis, diabetes, and full time employment and salary vs. hourly pay 
**Final model includes all variables from the full model except rural 
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Table III-4:  Hospitalization rates in the adherent and non-adherent populations 
before and after matching 
 
  % Hospitalized 
  Un-Matched Matched 
Adherent 8.2 9.4 
Non-Adherent 14.38 14.5 
Relative Risk 1.74 1.55 
95% CI for RR 1.22 - 2.49 1.07 - 2.25 
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Table III-5:  Demographic, clinical, and employment characteristics in the 
hospitalized and non-hospitalized populations before and after matching 
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Table III-6: Model fitting diagnostics for the likelihood of hospitalization, modeling 
the likelihood of hospitalization among adherent and non-adherent groups, 
controlling for other covariates following within the matched population 
Iteration Description 
Log 
Likelihood 
Difference 
in -2 Log 
Likelihood 
Model 
DF 
Critical 
Value 
(x2) P-value 
1 Full Model* 498.14   13     
2 
Full Model - 
Anxiety 498.154 0.028 12 3.84 >0.05 
3 
Full Model - 
Anxiety, Comb 498.366 0.424 11 3.84 >0.05 
4 
Full Model - 
Anxiety, Comb, 
Rural** 
499.658 2.584 10 3.84 >0.05 
5 
Full Model - 
Anxiety, Comb, 
Rural, Atyp 
508.198 17.08 9 3.84 <0.05 
*Full model Includes:  Adherence, Age, gender, rural, bipolar, anxiety, depression, other 
mental health diagnosis, atypical use, combination, switching, and primary coverage 
**Final model includes all variables from the full model except anxiety, combination use, and 
rural location 
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Table III-7:  Odds ratios for the likelihood of hospitalization 
  
  Point 
Estimate 
95%Confidence 
Limits 
Adherence        Adherent vs. non-adherent 0.627 0.394 0.999 
Demographic Male vs. Female 0.826 0.506 1.346 
Over 45 vs. Under 45 0.769 0.470 1.260 
Clinical Bipolar vs. No Bipolar 3.673 2.311 5.840 
 Depression vs. No Depression 2.285 1.363 3.832 
 Other Mental Health vs. None 3.511 2.064 5.972 
  SGA vs. FGA 1.764 0.915 3.401 
 FGA / SGA Combo vs. FGA 3.910 1.628 9.388 
 Switch vs. no switch 2.138 1.329 3.441 
Employment Responsible for coverage vs. 
Dependent 0.626 0.388 1.010 
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Table III-8:  Hospitalization rates in the adherent and non-adherent populations 
before and after matching 
 
  % Hospitalized 
  Un-Matched Matched 
Adherent 8.2 9.4 
Non-Adherent 14.38 14.5 
Relative Risk 1.74 1.55 
95% CI for RR 1.22 - 2.49 1.07 - 2.25 
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Table III-9:  Odds of hospitalization in the unmatched, matched, and matched 
with logistic regression 
  
% Hospitalized 
  
Un-Matched Matched 
Match w/ 
Statistical Model 
Odds Ratio 0.535 0.609 0.627 
p-value 0.0018 0.0203 0.0493 
95% CI for OR 0.36 - 0.80 0.40 - 0.93 0.39 - 0.999 
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